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ABSTRACT 
Advanced coronary artery disease (CAD) is the most frequently observed long term 
complication of cardiac transplantation. Studies report prevalence rates up to 70 per cent at 
five years post-transplant. In addition to immunologically mediated factors, conventional 
cardiovascular risk factors have been implicated in the development of CAD. The purpose of 
this research project was to investigate the cardiovascular profile and dietary intake of cardiac 
transplant recipients at twelve to twenty-four months post-transplant at St. Vincent's 
Hospital, Sydney. 
The study population consisted of 27 post-cardiac transplant patients. Data including body 
weight, serum lipid levels, blood pressure and the presence of diabetes mellitus in the post-
transplant period was retrospectively analysed from St. Vincent's Hospital records. Waist-to-
hip ratios (WHR) were measured at the time of participation in the study and compared to 
recommendations. Each participant was also interviewed for approximately one hour to 
obtain an extensive diet history. 
Analysis of anthropometric data indicated that body weight increased progressively 
throughout the post-transplant period. At twelve months post-transplant, 56 per cent of 
recipients were classified as overweight and one third of these obese. Mean weight gain was 
7.8 kg. Eighty eight per cent of the transplant population displayed WHR's larger than 
desirable. Cholesterol levels showed a steady post-transplant increase which reached 
statistical significance at three months post-transplant (p<0.01). Hypertension, as indicated 
by a diastolic blood pressure >95 mmHg or the administration of anti-hypertensive 
medications was present in 73 per cent of this population at 12 months post-operative. 
However, none of the participants displayed persistent uncontrolled hypertension. Post-
transplant diabetes mellitus was prevalent in 19 per cent of transplant recipients. An analysis 
of dietary intake data indicated that 63 per cent of transplant recipients had a fat intake greater 
vili 
than recommended, with a mean 31.7 per cent contribution to energy. Sodium and saturated 
fat intakes were also significantly greater than current healthy heart recommendations 
(p<0.01; p<0.05). 
The findings of this study suggest that cardiovascular risk factors are frequent in long term 
cardiac transplant recipients. Biochemical indicators and body weight should therefore be 
regularly monitored throughout the post-transplant period. Whilst more stringent efforts at 
weight control including intensive dietary intervention and encouragement of exercise within 
the first 12 months post-ttansplant, may be beneficial in improving cardiovascular profile and 
possibly assist in the prevention of cardiovascular complications such as CAD. 
2. Literature Review 
1. INTRODUCTION 
Cardiac transplant recipients are a high risk group for the development of long term 
cardiovascular complications including coronary artery disease. The aetiology of this 
disorder remains highly controversial, however conventional cardiovascular risk factors 
including hyperlipidaemia, obesity, hypertension, diabetes mellitus and dietary intake 
have been suggested to play a role. 
Anecdotal evidence from the St. Vincent's Hospital cardiac transplant population 
suggests that cardiovascular risk factors are prevalent in a large proportion of transplant 
recipients. Information regarding the profile of these risk factors and the long term 
dietary intake of this population, however, is largely unreported in Australia. This smdy 
attempts to address these issues by determining the long term cardiovascular profile and 
nutritional status of this group. In turn, this information will form the basis for an 
evaluation of the effectiveness of current nutrition services at St. Vincent's Hospital, 
Sydney. 
1.1 Aim 
The aim of this project is to investigate the cardiovascular profile and dietary intake of St. 
Vincent's Hospital cardiac transplant patients at twelve to twenty-four months post-
transplant. 
1.2 Objectives 
The objectives of this project include: 
1.2.1 To record blood lipid levels in cardiac transplant recipients and determine changes 
in lipid profile in the post-transplant period 
1.4.2 To record body weight in cardiac transplant recipients and determine the pattern of 
weight change in the post-transplant period 
1.4.3 To determine the body fat distribution of cardiac transplant recipients in the post-
transplant period 
1.2.4 To determine what proportion of cardiac transplant recipients display diabetes 
mellitus in the post-transplant period 
1.2.5 To determine what proportion of cardiac transplant recipients display hypertension 
in the post-transplant period 
1.2.6 To describe the usual dietary intake of cardiac transplant recipients in the post-
transplant period and compare with current dietary recommendations 
1.3 Definition of Terms 
Cardiomyopathy: 
A disease of the muscle of the heart. Can be dilated, hypertrophic or restrictive in its 
presentation. Can be idiopathic - of unknown cause or related to the outcome a variety of 
factors (eg. alcohol) (Weatherall et al 1989) 
Cardiovascular Risk Factors: 
Factors which have been identified as increasing the risk of coronary heart disease. 
Includes high blood pressure, obesity, elevated cholesterol, diabetes mellitus, diet, 
smoking and physical inactivity (National Heart Foundation 1989). 
Congestive Cardiac Failure: 
A disorder where the heart fails to adequately pump blood throughout the body. The 
result is circulatory congestion and sodium retention which leads to shortness of breath 
and oedema (Rothenberg and Chapman 1994). 
Coronary Artery Disease (CAD) : 
A disorder whereby lipid filled plaques develop on the inner walls of the coronary arteries 
narrowing the lumen and reducing blood flow to the heart. Also known as 
atherosclerosis (Rothenberg and Chapman 1994). 
Hyperlipidaemia: 
Elevated levels of lipids in the blood. These include cholesterol, lipoprotein subfractions 
(low density lipoprotein, high density lipoprotein) and triglycerides. 
Hypercholesterolaemia: 
Serum cholesterol levels exceeding 5.5 mmol / Litre (National Heart Foundation 1989) 
Hypertriglyceridaemia: 
Serum triglyceride levels exceeding 1.8 mmol / Litre (Curtin University of Technology 
1992) 
Hypertension: 
Blood pressure elevated above diastole 95mmHg and systole ISOmmHg (Stamler et al 
1993). Although a variety of definitions are used by different researchers. 
Immunosuppressants: 
Medications which act to suppress normal immune responses. In heart transplant patients 
these commonly include corticosteroids, cyclosporine and azathioprine (Reynolds 1989). 
Ischaemic Heart Disease (IHD): 
A disease whereby there is a decreased blood flow to the heart. Usually the result of 
atherosclerosis (Rothenberg and Chapman 1994). 
Myocarditis: 
Inflammation of the myocardium (heart muscle). Can be caused by viral infections, or 
bacteria, results in fatigue, dyspnoea and tachycardia (Weatherall et al 1989). 
Orthotopic Heart / Cardiac Transplantation: 
A medical procedure whereby the heart from a donor operatively replaces a recipients 
own failed heart. 
Peripartum Heart Disease: 
Dilated cardiomyopathy with pregnancy acting as a facilitator (Weatherall et al 1989). 
2.1 CORONARY ARTERY DISEASE IN CARDIAC 
TRANSPLANTATION 
Cardiac transplantation has become recognised as a successful treatment for end stage 
heart failure. Each year over 100 orthotopic heart transplants are performed in Australia 
and to date over 800 transplants have been completed among the four major transplant 
centres. The major indications for cardiac transplantation include ischaemic heart disease, 
idiopathic cardiomyopathy, myocarditis and congenital heart disease. Survival rates for 
transplant recipients have improved significantly over the past two decades, reaching 86 
per cent at one year and approximately 78 per cent at five years (Australian & New 
Zealand Cardiothoracic Organ Transplant Registry 1994). Mortality during the first year 
is related to operative complications, infection and rejection (Mann 1992). However, the 
most frequently observed long term complication of cardiac transplantation is an 
accelerated form of coronary artery disease (CAD) (Scott and Dark 1992). 
The clinical presentation of post-transplant CAD often differs from conventional 
atherosclerosis. It frequently develops in smaller coronary vessels, is concentric, diffuse 
and characteristically occurs at a rapid rate without the development of a collateral blood 
supply (Mullins et al 1992). Less commonly, transplant CAD may appear as a plaque 
which is indistinguishable from conventional atherosclerosis (Schroeder et al 1992). 
Transplant CAD is often clinically silent in its development, as a result of denervation 
(Gao et al 1990). Mortality due to CAD is commonly the result of fatal myocardial 
infarcts, congestive heart failure and cardiac arrhythmia's. In addition, graft failure as a 
result of CAD is a frequent indication for re-transplantation (Schroeder et al 1992). 
Prevalence rates for post-transplant CAD have been reported from two to 28 per cent at 
one year post-transplant and up to 70 per cent at five years (Gao et al 1989, Narrod et al 
1989, Mullins et al 1992). Survival rates appear to be a function of CAD advancement. 
Mullins et al (1992) reported a 60 to 80 per cent survival rate three years after CAD 
diagnosis. However, survival rates in more advanced CAD are much poorer. Three 
year survival rates of 22 per cent have been reported for CAD affecting a single vessel 
with greater than 40 per cent stenoses, whilst survival with triple vessel disease over the 
same period is as low as 6 per cent (Keogh et al 1991). 
A number of factors have been suggested to predispose the heart transplant recipient to 
CAD, although the relative contribution of each has not been established. It has been 
suggested that post-transplant CAD is an immunological mediated disease (Stovin et al 
1991). It has been related to donor specific cytotoxic antibodies and cellular rejection. 
Uretsky et al (1987) in studies on CAD, reported that transplant recipients with more than 
two episodes of rejection within the first year post-transplant, had an increased risk of 
developing CAD. However, these findings have not been consistently reported in the 
literature (Stovin et al 1991). 
Viral infections, notably cytomegalovirus (CMV) have been shown to correlate with the 
development of post-transplant CAD (Stovin et al 1991). CMV has been reported in up 
to 90 per cent of heart transplant recipients (Dummer 1990). It has been suggested that 
CMV may be an initiator of atherosclerosis through its damaging influence on the 
endothelium (Stovin et al 1991). In animal studies, the virus has been shown to increase 
cholesterol incorporation into the arterial intima and alter the normal synthesis and 
metabolism of cholesterol (Miller 1991). Studies on the influence of CMV have produced 
mixed results with some reporting a relationship (Stovin et al 1991) and others finding no 
significant influence on CAD development (Sharpies et al 1991). 
Donor and recipient characteristics have both been suggested to play a role in post-
transplant CAD. A number of studies have indicated that CAD occurs more commonly in 
recipients of hearts from older donors (Sharpies et al 1991). Older recipients themselves, 
notably over the age of 50 years, may also be at greater risk of post-transplant CAD. The 
sex of both donor and recipient may additionally influence CAD development (Sharpies et 
al 1991), as might donor ischaemic time (Miller 1991). Further, certain tissue type 
mismatches may be predictive of CAD development (Stovin et al 1991). 
There is some evidence that pre-operative diagnosis may be related to CAD development. 
Transplant recipients with ischaemic heart disease as the initial cause of heart failure, have 
been shown in some studies to be at an increased risk of developing this accelerated form 
of CAD (Sharpies et al 1991). In comparison recipients with a diagnosed cardiovascular 
disease without atherosclerotic involvement, such as a cardiomyopathy or valvular 
disease may be at lower risk. Again, this is controversial in the literature. 
A relationship between immunosuppressive medications including cyclosporine and 
corticosteroids and CAD has been suggested. It is thought that prolonged treatment with 
these medications may directly damage graft vessels (Dummer 1990). Indirect effects 
such as hyperlipidaemia, hypertension and glucose intolerance have also been 
demonstrated. 
Conventional cardiovascular risk factors including hyperlipidaema, diabetes mellitus, 
obesity and diet have also been implicated in this disorder. Due to the multi-factorial 
nature of post-transplant CAD however, the role of these risk factors has not been 
delineated. Eich et al (1990) proposed that the combined effect of endothelial damage and 
associated risk factors may play a key role in post-transplant CAD. In this model, 
immunosuppressive medications, immune responses, and viral infections combined with 
diabetes mellitus and dyslipidaemia result in damage to the endothelium, platelet 
aggregation, intimal smooth muscle proliferation and consequent CAD (refer to Figure 
one). The aetiology, significance and role of these conventional risk factors in post 
transplant CAD will be reviewed in each of the chapters to follow. 
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Figure 2.1.1 Predisposing factors to the development of CAD in cardiac 
transplant recipients (Adapted from Eich et al (1990)) 
2.2 HYPERLIPIDAEMIA 
2.2.1. Hyperlipidaemia in Coronary Heart Disease 
Raised plasma lipids have been clearly established as a strong and independent risk factor 
for the development of coronary heart disease in the general population. 
Hyperlipidaemia, which includes elevations in total cholesterol, cholesterol sub-fractions 
and triglyceride levels, increases cardiovascular risk through its influence on the 
development of atherosclerosis (Gotto et al 1990). 
In the general population, the risk of heart disease begins to increase at total plasma 
cholesterol levels above 3.9 mmol/L. The most considerable risk, however, occurs at 
cholesterol levels in excess of 5.2 mmol/L (Keogh 1987). The low density lipoprotein 
(LDL) sub-fraction of cholesterol poses a significantly increased risk as a result of its 
atherogenicity. High density lipoprotein (HDL) cholesterol on the other hand has been 
shown to have a protective effect on cardiovascular health (Romm et al 1991). Further, 
plasma triglycerides have been identified as a risk factor for CHD. However, this risk is 
thought to be influenced by the association of hypertriglyceridaemia with low HDL 
cholesterol, obesity and insulin resistance. It appears that elevated triglycerides pose 
cardiovascular risk when HDL cholesterol is depressed in the presence of elevated total 
cholesterol (Castelli 1986). 
The role of hyperlipidaemia in coronary heart disease has been consistently reported in 
both epidemiological and clinical studies. The Multiple Risk Factor Intervention Trial, a 
randomised primary prevention study, for example, provided epidemiological data to 
suggest that mortality from heart disease was strongly associated with serum cholesterol 
levels (Multiple Risk Factor Intervention Trial Research Group 1982). Similarly, other 
studies such as those from Framingham and the Lipid Research Clinics have reported 
comparable evidence for the adverse cardiovascular consequences of hyperlipidaemia 
(Kannel et al 1971; Lipid Research Clinics Program 1984). 
2.2.2 Cardiac Transplant Hyperlipidaemia 
Considering the evidence supporting a link between elevated blood lipids and heart 
disease, it is possible that hyperlipidaemia plays a role in the establishment of post-
transplant CAD. Studies by Eich et al (1991) support this hypothesis. In a retrospective 
review of 38 heart transplant recipients, they found that hypercholesterolaemia at six 
months post-transplant was a strong predictor of subsequent CAD. Similarly, Barbir et 
al (1991), in comparing cumulative cardiovascular risk in patients with and without 
hyperlipidaemia, indicated that the probability of CAD was greater in transplant 
recipients with cholesterol above 5.8 mmol/L. In the same study, the incidence of CAD 
was greater in patients with triglyceride levels above 1.4 mmol/L. Another study by 
Winters et al (1990), also confirmed a significant relationship. In an analysis of the 
extent of coronary arteriopathy in transplant recipients, they reported that patients with 
higher mean cholesterol and triglyceride levels had a significantly more luminal 
narrowing. These results and those from a number of other studies clearly suggest a role 
for hyperlipidaemia in the evolution of CAD. However, some researchers have 
suggested that hyperlipidaemia occurring in combination with other factors such as 
cytotoxic antibodies and HLA mismatch is necessary for the development of CAD in this 
setting (Ballantyne et al 1987). 
Hyperlipidaemia is frequently demonstrated in both renal and heart transplant recipients. 
The incidence in heart transplant patients has been reported to vary from 33 to 83 per cent 
for hypercholesterolaemia (Keogh et al 1988; Rudas et al 1990). Hypertriglyceridaemia 
has been found in up to 10 per cent of the same population (Keogh et al 1988). There is 
considerable variability in the literature regarding the predominate lipid abnormalities. 
Grady and Herold (1988) found that elevations in post-transplant triglyceride and total 
cholesterol were most frequent. They reported an increase in mean triglyceride 
concentrations from 3.5 to 5.7 mmol/L. Whilst total cholesterol increased from 4.6 to 
6.8 mmol/L. Keogh et al (1988) confirmed similar increases in total cholesterol, 
however, changes in triglycerides were less frequent. Elevations in lipid sub-fractions 
have also been reported. Becker et al (1988) in a study of recipients from a number of 
heart transplant centres, discovered elevations in LDL and HDL cholesterol as well as 
total cholesterol and triglyceride levels. Thirty eight per cent of these patients were above 
the 90th percentile for total cholesterol when compared to a reference population, 
indicating that hyperlipidaemia is a particular concern for this population. 
In heart transplant recipients, hyperlipidaemia appears to occur as a progressive increase 
in lipid levels within the first twelve months post-transplant. Although this pattern has 
shown variation in different studies. Keogh et al (1988) in a study on twenty-two heart 
transplant recipients reported mean serum cholesterol increases which peaked at 3 months 
post-transplant. At twelve months post-transplant a significant degree of 
hypercholesterolaemia ( > 6.5 mmol/L) was found in nine of the transplant patients. 
Mean serum triglyceride levels were also found to be higher in the post-transplant period. 
Similarly, Ballantyne et al (1992) in a larger study, reported elevated total cholesterol and 
triglycerides in the first three months following transplantation. They found no 
significant changes in lipid profile after this time. The findings of Lake et al (1993) 
however, propose a different pattern of hyperlipidaemia. In a prospective study of 89 
transplant recipients, they noted increases in total cholesterol, LDL cholesterol and blood 
triglycerides at 12 months, which remained elevated at 24 months post-transplant. Earlier 
post-operative elevations in lipids have also been suggested by some researchers. 
Stamler et al (1988), for example, reported significant elevations in both LDL and total 
cholesterol at 2 weeks post-transplant. At 3 months, these levels peaked and remained 
elevated for 12 months post-operatively. In the same study triglyceride and HDL 
elevations were noted at 3 months post-transplant but did not reach statistical 
significance. 
3 0009 03143469 4 
Overall, the majority of studies report evidence of hyperlipidaemia in cardiac transplant 
recipients. Although inconsistencies in the literature are evident, it is important to 
recognise that there are a number of potential sources of inaccuracy in determining blood 
lipid levels. In the pre-transplant period, patients are susceptible to cardiac cachexia, liver 
dysfunction and in some cases myocardial infarcts, all of which are known to modify 
serum lipids. Similarly, blood samples taken immediately post-operatively may not 
reflect true lipid values due to the metabolic stresses of major surgery (Rosenson 1993; 
Ballantyne et al 1987). Hence data which suggests changes in lipid profiles from pre to 
post-transplant must be interpreted with care. Further, drawing comparisons between 
studies is difficult with different variables, for example, medication protocols potentially 
affecting lipid levels. 
The mechanism by which hyperlipidaemia develops in the post-transplant period is not 
clear, but immunosuppressive treatment has been implicated as a major cause. The 
negative effects of corticosteroids on lipid levels have been widely reported in patients 
receiving long-term immunosuppression for inflammatory and connective tissue 
disorders (Bagdale et al 1970; El-Shaboury and Hayes 1973). In a healthy population, 
the steroid prednisone has been shown to induce elevations in plasma total cholesterol, 
LDL cholesterol and HDL cholesterol within 48 hours of administration (Zimmerman et 
al 1984). More recently similar findings have been reported in heart transplant recipients. 
The most convincing evidence comes from studies which suggest that cholesterol levels 
decrease when patients are tapered off steroids. For example, Renuld et al (1989) found 
that withdrawal of the corticosteroid, prednisone was associated with cholesterol levels of 
21 to 26 per cent lower than patients maintained on prednisone therapy. Similar, 
although less dramatic findings have been reported in other studies (Lake et al 1993). 
The influence of corticosteroids on blood lipids is thought to occur as a result of 
decreased post-heparin lipolytic activity, glucose intolerance and increased accumulation 
of dietary fat (Elasser and von Eickstedt 1992). Although these findings have not been 
demonstrated in all studies of hpid elevations in transplant patients (Superko et al 1990). 
The powerful immunosuppressant, cyclosporine has also been demonstrated to adversely 
affect lipid profile. Increased levels of total cholesterol and triglycerides have been 
reported in both renal and heart transplant recipients with cyclosporine administration 
(Harris et al 1986; Superko et al 1990; Winters et al 1990). Total cholesterol elevations 
are thought to be the result of increased LDL cholesterol. Whilst cyclosporine has been 
inversely related to lipoprotein lipase and hence elevated blood triglycerides (Superko et 
al 1990). Several researchers have reported an adverse effect of cyclosporine on lipid 
levels. Stamler et al (1988) demonstrated that changes in lipid levels in patients receiving 
cyclosporine differed from that with other immunosuppressive regimens, an effect which 
they related to the hepatotoxic effects of this drug. However, failure to control for other 
variables, including diet and medication makes the significance of these findings 
questionable. More convincing evidence comes from a trials undertaken by Ballantyne et 
al (1989). In comparing the lipid profile of patients treated with cyclosporine and those 
receiving a placebo, they reported significant increases of 21 per cent in total cholesterol 
and 31 per cent in LDL cholesterol. In comparison, Becker et al (1988), found that the 
influence of cyclosporine on lipid levels was insignificant. However, they reported that 
cumulative prednisone exposure was the strongest predictor of unfavourable lipid 
profiles. Other studies have suggested that cyclosporine therapy enhances the effect of 
corticosteroids on serum lipids (Johnson 1992). However, there is no clear consensus in 
the literature regarding the exact role that cyclosporine plays in the establishment of 
hyperUpidaemia. 
Obesity following heart transplantation is a possible contributing factor to the 
development of lipid abnormalities. Excessive accumulation of body fat, as prevalent in 
the transplant population has been associated with poor lipid profiles (Bonora et al 1991). 
A possible role in the development of post-transplant hyperlipidaemia is therefore 
evident. Studies by Keogh et al (1988) support this suggestion. In research on 
hyperlipidaemia they demonstrated a correlation between body weight and serum lipid 
levels. It was suggested that 81 per cent of the variation in total cholesterol and 72 per 
cent of that in triglycerides could be explained by increases in body weight. Similariy, 
Rudas et al (1990) reported that the presence of obesity at one year post-transplant was 
significantly associated with hyperlipidaemia. Studies on renal transplant recipients have 
produced similar findings. Vathsala et al (1989) for example, demonstrated that 
hypertriglyceridaemia in renal transplanted patients was one of several factors 
aetiologically linked to obesity. Considering the initial cause of weight gain is often 
corticosteroid related, the development of lipid abnormities via obesity may therefore be a 
further adverse consequence of steroid administration. 
Initial diagnosis and pre-transplant hyperlipidaemia have also been suggested as 
predictors of lipid profiles following cardiac transplantation. Studies have found that 
patients with a history of lipid abnormalities show higher post-operative lipid values. 
Lake et al (1993) reported evidence of this at both 12 and 24 months post-transplant. 
These findings agree with those of Rudas et al (1990) which suggest that hyperlipidaemia 
in the post-transplant period results from the normalisation of cardiac function. 
Elsewhere, a pre-operative diagnosis of coronary artery disease (which is associated with 
lipid abnormalities) has been reported as being predictive of post-transplant 
hyperlipidaemia (Rudas et al 1990; Keogh et al 1988; Taylor et al 1989). Although there 
is considerable support for this relationship it has not been consistently reported in the 
literature. 
As a modifiable cardiovascular risk factor, prevention or effective treatment of 
hyperlipidaemia would clearly be of some benefit in CAD risk modification. Initial 
attempts to control lipid elevation through pharmacological lipid lowering agents were 
largely unsuccessful (Keogh 1987). These medications resulted in a number of adverse 
side effects and demonstrated little benefit on improving lipid profiles. More recently 
however, newer treatment protocols have demonstrated improved outcomes. However, 
potential side effects and drug interactions remain important considerations for these 
patients (Ballantyne et al 1989). The efficacy of diet and lifestyle modifications in this 
setting have been controversial. These will be discussed further in chapters to follow. 
In summary, hyperlipidaemia is a significant complication of heart transplantation. 
Unlike conventional hyperlipidaemia, the aetiology of this disorder has not been 
established. A multitude of factors have been implicated, yet none has been consistently 
demonstrated. It is possible that a combination of immunosuppressive medication, 
obesity, pre-transplant lipid status and pre-operative diagnosis contribute to lipid 
abnormalities in this setting. Further, renal insufficiency, diabetes, anti-hypertensive 
medications, recipient age, dietary intake and ethanol may exacerbate changes in lipid 
profile (Lake et al 1993). Clearly, an effective means of preventing lipid abnormalities 
would be beneficial to the cardiovascular profile of these patients and possibly alter the 
pathway for CAD development 
2.3 OBESITY 
2.3.1 Obesity and Coronary Heart Disease 
Obesity, the excessive accumulation of body fat has been strongly correlated with the 
development of coronary heart disease. Obese individuals have been reported to have a 
an increased risk of heart disease, which is associated with considerable morbidity and 
mortality (Noppa et al 1980). The role of obesity as a cardiovascular risk factor has been 
shown to be both independent and via the influence on other risk factors (Hubert et al 
1983). 
The health implications of obesity have been widely reported (Larrson et al 1981; Garrow 
1991). Large controlled studies have demonstrated a variety of metabolic and 
cardiovascular consequences in obese populations. Insulin resistance is one such factor 
which has been related to the development of diabetes mellitus and poor lipid profiles, 
hence the risk of coronary heart disease (Hartz et al 1983; Felber 1992). Hypertension 
has also be reported as a significant complication which may have initiating effects on the 
process of atherosclerosis (Stamler et al 1978). In addition, abnormalities in serum 
cholesterol and triglycerides have been demonstrated to occur in obesity (Forde et al 
1986; Bonora et al 1991). Further, obesity has been shown to increase cardiac output via 
its influence on blood volume, stroke volume and left ventricular end-diastolic volume. 
Hence the consequences may be left ventricular hypertrophy and cardiac failure (Hagan et 
al 1990). As a result, obesity has negative implications for cardiovascular profile and thus 
the risk of coronary heart disease. 
2.3.2. Body Fat Distribution and Coronary Heart Disease 
There is evidence that the distribution of body fat may pose additional cardiovascular 
risk. Upper body obesity (android) has been more strongly associated with the myriad of 
metabolic aberrations including hyperinsulinaemia, diabetes mellitus, hypertension and 
dyslipidaemia (Egger 1992). In contrast obesity of the lower body (gynoid) has been 
shown to have fewer health complications (Despres et al 1990). As a result, the android 
pattern of obesity has been associated with an increased risk of coronary heart disease 
and consequent morbidity and mortality (Donahue et al 1987; Ducimetiere and Richard 
1989; Hartz et al 1990; Rimm et al 1995). 
The metabolic consequences of increased adiposity in the upper body region are related to 
the presence of visceral or intra-abdominal fat (Zamboni et al 1994). As opposed to 
subcutaneous upper body fat, that of the intra-abdominal region lies deeper within the 
abdominal cavity and is more metabolically active (Calvert 1991). Consequentially, it 
influences insulin, glucose, fatty acid and lipoprotein metabolism (Despres et al 1990). 
Although the mechanisms by which these disturbances occur are not completely 
understood it is evident that the android pattern of obesity has multiple cardiovascular 
implications. This is supported by recent research which has described an independent 
role for central obesity in the development of cardiovascular disease (Hartz et al 1990). 
However, the fact that abdominal fat increases with age and differs amongst the sexes 
makes the independent contribution of this pattern of body shape in the absence of 
obesity per se, controversial. Some researchers have suggested that increased abdominal 
fat, as indicated by anthropometric measures, enhances the detrimental effects of obesity 
on metabolism (Depres 1992). Thus an increased body weight in conjunction with a 
large abdominal region of adiposity may be predictive of cardiovascular risk. 
2.3.3 Obesity and Cardiac Transplantation 
Excessive weight gain is a frequently observed complication of heart transplantation 
which has been identified as a prognostic factor in the progression of CAD (Poindexter et 
al 1990). Prior to transplantation patients may be underweight as a result of 
compromised cardiac function, suppressed appetite and catabolism. Following 
transplantation however, significant weight gain often resulting in obesity has been 
documented in a large proportion of patients (Robert et al 1990). 
Obesity is thought to influence the risk of transplant CAD through similar metabolic and 
cardiovascular pathways as non-transplant coronary heart disease. Winters et al (1990) 
in a study of failed human heart allografts reported that body mass index was, of forty 
risk factors studied, the single most predictive in the development of coronary 
arteriopathy. However, this data is not consistently supported in the literature. Other 
researchers have failed to demonstrate obesity as a primary risk factor for the 
development of CAD, hypertension or hyperlipidaemia, indicating that other factors may 
play a role (Poindexter et al 1990). 
The most frequently demonstrated pattern of weight gain appears to be a steady increase 
throughout the post-transplant period. Baker et al (1992) demonstrated that changes from 
baseline weight in transplant recipients were significant at bi-monthly post-transplant 
intervals, with significant increases between each measure. In another study, ideal body 
weight increased from 102 per cent at surgery to 113 per cent at one year post-transplant 
(Poindexter et al 1990). Twenty seven per cent of the patients in this study were 
classified as obese. Similarly, Grady et al (1990) reported significant weight increases in 
the post-transplant population which remained elevated over the first three post-operative 
years. A comparable pattern has been shown in other organ transplant populations 
(Gardiner 1993). 
Corticosteroid administration has been implicated as the major cause of weight gain 
following transplantation. Heart transplant recipients are prescribed corticosteroids as a 
means of suppressing immune responses which may initiate rejection of the donor heart 
(Reynolds 1989). Long term patients are usually sustained on low "maintenance" doses, 
whilst dosage is increased in periods of acute rejection. The means by which 
corticosteroids induce changes in body weight can be attributed to both the stimulation of 
appetite and metabolic effects as a result of increased gluconeogenesis (Elasser and von 
Eickstedt 1992). An additional side effect, Cushings Syndrome, whereby the function 
of the adrenal cortex is suppressed, is related to the development of obesity, facial 
rounding and oedema (Garrow 1985). Early studies on the side effects of corticosteroids 
demonstrated that muscle wasting and increased fat stores were commonly exhibited 
(Schnieder 1977). Evidence of fat redistribution from peripheral to truncal regions has 
also been suggested (Melby 1974). Hence the profile of weight changes appear to be 
gain in total body fat (and resultant weight) as well as notable increases in adipose in the 
abdominal region as a result of corticosteroid treatment. This pattern appears to be 
similar to that which poses the greatest cardiovascular risk. 
Studies on corticosteroid-free immunosuppressed patients support the earlier evidence for 
a role of steroid therapy in weight gain. Hagan et al (1990) in a retrospective comparison 
of steroid versus non-steroid treated heart transplant recipients reported a mean weight 
difference of 4.2 kilograms between the two groups, with those receiving steroids being 
of a significantly greater weight. It is notable however, that the researchers did not 
control for the influence of dietary intake, hence weight changes may not be attributable 
solely to steroid therapy. Another study by Lake et al (1993) found similar weight 
increases with steroid administration, however these did not reach statistical significance. 
Interestingly, it was also demonstrated in both of the above mentioned studies, that those 
who were obese prior to undergoing transplantation gained significantly more weight in 
the post-transplant period. Changes in body fat distribution were not examined by these 
investigators. The findings of the available research to date suggest a probable role for 
corticosteroid induced weight gain. Further reseai'ch would be beneficial to discriminate 
contributing factors. 
Despite anecdotal evidence for changes in body composition in heart transplant recipients, 
supporting evidence from the literature is scarce. One study undertaken by Kavanaugh et 
al (1989) using skinfold measurements assessed 36 heart transplant patients at a mean 
time of seven months post-transplant. They described changes in body composition as 
reductions in fat-free mass, body mass index and percentage body fat. These findings 
differ from the proposed body composition changes suggested by other researchers. 
However only six of the subjects were receiving steroid therapy during the study period, 
the results therefore are not comparable with corticosteroid immunosuppressed transplant 
populations. More recently the body composition of transplant recipients maintained on 
steroid therapy have been assessed using hydrostatic weighing. Keteyian et al (1992) in 
a study on 24 patients at a mean 21 months post-transplant noted increases in body 
weight and percentage body fat which reached statistical significance. The mean weight 
gain for this group of patients was 9.7 kilograms and body composition was reported to 
be 34 per cent fat, ranking participants on the 15th percentile for body fat when compared 
to the general population. The prednisone dose and length of post-operative period were 
inversely related although not additive in their effect on body density. The weight 
changes indicated in this study are comparable with the 12 kilogram increase at 24 
months post-transplant reported by Poindexter et al (1990). However, it is considerably 
greater than the four kilograms weight gain demonstrated in another study (Keogh et al 
1988). These inconsistencies are possibly attributed to the differing periods at which 
patients were assessed or variations in medication protocols. 
In heart transplant recipients, evidence for increased abdominal or android fat distribution 
remains largely undocumented. In other patients populations treated with steroids, 
however the proposed increased abdominal distribution of body fat has been questioned. 
Horber et al (1986) using computed tomography found that patients on long term 
glucocorticoids exhibited normal or even increased mid thigh fat areas as well as 
increased central fat stores. This led the researchers to conclude that the traditional 
concept of fat redistribution from the peripheral to central regions as a result of steroid 
treatment requires revision. It is still notable however, that both intra-abdominal and 
subcutaneous central adiposity, did in fact increase and muscle wasting as originally 
described was evident. Therefore although a typical android pattern may not be 
manifested in these patients, the metabolic implications of increased abdominal fat stores 
are still likely to result. Further evidence specifically related to heart transplant recipients 
is needed to clarify these issues. 
Apart from corticosteroids, a number of other factors have been suggested to predispose 
transplant recipient to obesity. Improvements in quality of life for example, may play a 
major role in post-transplant weight gain. Patients frequently exhibit enhanced feelings 
of well being and thus are able to resume an adequate oral diet. In the long term, this 
may result in excess in caloric intake. In addition improved gastrointestinal absorption of 
nutrients in post-transplant patients and may impact upon body weight (Keogh 1987). 
Further, factors such as physical inactivity and fluid retention may contribute to weight 
changes (Grady and Herold 1988). 
In summary, it is evident that overweight and obesity are significant complications of 
cardiac transplantation. The underlying cause of this appears to be multifactorial. In the 
long term transplant recipients, maintaining a healthy weight is likely have desirable 
consequences on lipid profiles, blood pressure, glucose tolerance and cardiac function 
which may have positive impHcations for CAD prevention. 
2.4 DIABETES MELLITUS 
2.4.1. Diabetes and Coronary Heart Disease 
Diabetes mellitus is a disorder characterised by a deficiency or reduced sensitivity of 
insulin with resultant blood glucose elevations and metabolic aberrations. In the long 
term, both insulin dependant and non-insulin dependant individuals are at increased risk 
of developing multiple chronic complications including atherosclerosis (McDonald and 
Roberts 1990). Consequently, coronary heart disease affects a large proportion of 
individuals with diabetes and is a major cause of morbidity and mortality in this 
population (Zimmet and King 1986; Moss et al 1991; De Stafano 1993). 
The development of atherosclerosis and the resultant cardiovascular complications have 
been attributed to the interaction of several key factors. Lipid abnormalities including 
elevations in total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels 
are extensively demonstrated in this population and are thought to result from alterations 
in lipoprotein metabolism (Briones et al 1984; Reaven 1987). Plasma lipids have been 
shown to vary depending on glycaemic control, body fat composition and the 
development of diabetes related complications such as nephropathy (Dunn 1990). 
Diabetes has been related to hypertension, which may induce endothelial damage thus 
atherosclerosis. There is also evidence of hyperinsulinaemia playing a role in the 
atherosclerotic process through its influence on lipid synthesis and deposition (Skinner 
1993). Other contributing factors include obesity and blood platelet malfunctioning both 
of which are prevalent in diabetes mellitus (Felber 1992; MacRury et al 1993). 
Large controlled studies have shown that the occurrence of coronary heart disease is 
increased in diabetes mellitus. The Framingham Study demonstrated that the incidence 
of cardiovascular complications was doubled in diabetic males and tripled in diabetic 
females when compared to control subjects (Kannel and McGee 1979). More recently. 
other investigators have reported that blood glucose concentrations are correlated with 
cardiovascular risk (Welin et al 1992). Numerous other studies have confirmed such a 
relationship between diabetes mellitus and coronary heart disease (De Stafano et al 1993; 
Stamler et al 1984). 
2.4.2 Diabetes and Cardiac Transplantation 
Diabetes Mellitus has been demonstrated in various studies on post-cardiac transplant 
recipients (Ladowski et al 1989; Rhenman et al 1988). There are three possible scenarios 
which may explain the development of diabetes in this setting. Firstly, recipients may 
exhibit pre-existing insulin or non-insulin dependant diabetes (Rheman et al 1988). 
Alternatively, post-transplant obesity may initiate the glucose intolerance and 
hyperinsulinaemia characteristic of diabetes. A final possibility is the use of 
immunosuppressant medications which may induce metabolic changes and lead to the 
development diabetes mellitus (Elasser and von Eickstedt 1992). It is also plausible that a 
combination of these factors results in the post-transplant development of this disorder. 
Although diabetes mellitus has been established as a risk factor for the coronary heart 
disease seen in the general population, evidence for a role in post-transplant CAD has not 
been widely reported. A study by Ladowski et al (1989) attempted to determine the 
impact of post-transplant diabetes mellitus on survival following heart transplantation. 
They reported a three year survival rate of 75 per cent in transplant recipients with 
diabetes which compares favourably with survival for the non-diabetic transplant 
population. Similar findings have been reported by other researchers (Rhenman et al 
1988). In the same study, Ladowski et al (1989) failed to demonstrate any difference in 
the development of CAD in patients with diabetes when compared with the total 
transplant population. Eich et al (1991) additionally failed to find any differences in the 
incidence of CAD between patients with and without diabetes at six months post-
transplant. However, the small sample size and demonstrated low incidence of CAD in 
the total population at six months post-transplant make the validity of these findings 
questionable. Overall, the present lack of research makes it difficult to either support or 
dispute the role of post-transplant diabetes mellitus in CAD. However, it is still 
important to recognise that diabetes in the post-transplant period may have adverse 
consequences for the development of other risk factors, such as hyperlipidaemia (Taylor 
etal 1989). 
Diabetes mellitus has been reported to affect from 8 to 14 per cent of the cardiac 
transplant population (Utresky et al 1987; Ladowski et al 1989). This is comparable with 
the prevalence rates demonstrated in other organ transplant populations (Boudreaux et al 
1987). However, it is possible in heart transplant patients that glucose intolerance and 
hyperinsulinaemia occur frequently without the development of diabetes per se. This 
suggestion is supported by Kemna et al (1994) who reported that male heart transplant 
recipients had significantly higher plasma glucose and insulin concentrations in response 
to an oral glucose tolerance test than matched controls. A large proportion of transplant 
recipients may therefore be at high risk of developing this disorder. 
Corticosteroid administration is the most widely reported aetiological factor in the 
development of diabetes following cardiac transplantation. The term steroid diabetes has 
been used to describe the effects of this immunosuppressant on carbohydrate metabolism 
and thus blood glucose levels. Corticosteroids have been shown to enhance 
gluconeogenesis, with resultant increases in blood glucose levels of up to 20 per cent. In 
addition, both tolerance to glucose and insulin sensitivity generally decrease. Pancreatic 
function however, is not affected by steroid administration and ketosis does not 
characteristically develop. The result is a dose dependant steroid induced diabetes 
mellitus distinguished by a low insulin sensitivity and renal glucose threshold (Elasser 
and von Eickstedt 1992). Studies in recipients of renal transplants have demonstrated the 
existence of a relationship between steroid therapy and the development of diabetes 
mellitus (Friedman et al 1985; Boudreaux et al 1987). In contrast, the few studies on 
heart transplant patients to date have failed to find this effect, suggesting that other factors 
may play a role in this disorder (Ladowski et al 1989). 
The immunosuppressant cyclosporine may be additional factor which contributes to the 
development of post-transplant diabetes mellitus. Animal studies offer support for this 
hypothesis. Experiments on rats have demonstrated that cyclosporine has the potential to 
impair glucose tolerance, initiate blood glucose elevations and adversely affect pancreatic 
islet function (Hahn et al 1986). Thus a cyclosporine induced diabetes mellitus may 
result. The animal model however, is not strongly supported in studies on human 
transplant populations. Ladowski et al (1989) failed to find any relationship between 
cyclosporine dosage and the development of diabetes in heart transplant recipients. 
Whilst Harris et al (1986) reported similar findings in recipients of renal transplants. 
Further, Boudreaux et al (1987) indicated that cyclosporine combined with other 
immunosuppressive medications and recipient characteristics, such as age, contributed to 
the development of diabetes mellitus following renal transplantation. Again, the scarcity 
of evidence in the literature, particularly with the heart transplant population, make 
conclusions regarding cyclosporine and post-transplant diabetes, controversial. 
Studies reporting on other factors which may predispose heart transplant recipients to 
diabetes mellitus are limited. Obesity is one such factor which is known to enhance 
glucose intolerance, yet its role in post-transplant diabetes mellitus has not been 
elucidated. One study by Boudreaux et al (1987) on renal transplant recipients reported 
that the incidence of post-transplant diabetes mellitus was greater in patients weighing 
over 70 kilograms. Similar evidence in the heart transplant population has not been 
reported in the literature. Other factors potentially influencing the development of 
diabetes, such as age and sex have also been largely ignored in the literature to date. 
In summary, although post-transplant diabetes mellitus has not been demonstrated to 
affect CAD risk as such, strong evidence from studies in the non-transplant population 
clearly suggest that it is a potential contributing factor. As a result, efforts to reduce the 
occurrence of this disorder and enhance glycaemic control may be beneficial to the long 
term cardiovascular profile of transplant recipients. Such attempts would be improved 
with further research into initiating factors in the development of post-transplant diabetes 
mellitus. 
2.5 HYPERTENSION 
2.5.1 Hypertension in Coronary Heart Disease 
Hypertension has been well established as a major risk factor for coronary heart disease 
which affects a large proportion of the Australian population (National Heart Foundation 
1989). A diastolic and a systolic blood pressure exceeding 95 and 150 mmHg 
respectively characterise this disorder which has been shown to increase the risk of 
coronary heart disease by up to 40 per cent (Stamler et al 1993). 
The cardiovascular effects of long term elevations in blood pressure are significant. 
Hypertension has been shown to accelerate the development of atherosclerosis through its 
damaging effects on the endothelium (Weber 1994). Uncontrolled blood pressure also 
increases the workload of the heart and may contribute to cardiac failure (Skinner 1993). 
In addition, hypertension frequently co-exists with other risk factors including 
hyperlipidaemia, obesity and diabetes mellitus (Hansson 1992). Thus the risk of heart 
disease is further increased. 
Multiple long term studies have documented hypertension as a cardiovascular risk factor. 
The Multiple Risk Factor Intervention Trial demonstrated that the relationship between 
blood pressure and coronary heart disease was continuous, graded, strong and 
independent of other risk factors (Neaton and Wentworth 1992). In the same study, 
hypertension was estimated to be responsible for 49 per cent of deaths from heart 
disease. An earlier study reported that the risk of mortality from heart disease was 1.6 
times higher in males with a systolic blood pressure above 130 mmHg (Paffenberger et al 
1978). A number of more recent published reports also document the significant 
relationship of blood pressure elevations to coronary heart disease risk (Reed et al 1987; 
Kannel 1990). 
2.5.2 Hypertension following Cardiac Transplantation 
In heart transplant recipients, hypertension is the most frequently observed of all 
conventional cardiovascular risk factors. The role of this disorder in the CAD seen in 
heart transplant recipients however, is not clear. Some studies have failed to demonstrate 
any correlation between the presence of this anomaly and the subsequent development of 
post-transplant CAD. Eich et al (1991) for example, in a study of 38 heart transplant 
recipients reported that the relationship between hypertension and CAD was insignificant 
at three years post-transplant. However, the small sample size used in this study may not 
accurately demonstrate the true implications of uncontrolled hypertension. In contrast, 
there is some evidence to suggest that hypertension may be a contributing factor to the 
genesis of post-transplant CAD. Radovancevic et al (1990) confirmed that post-operative 
arterial hypertension correlated significantly with the onset of CAD. Whilst, Winters et al 
(1990) reported that a diastolic blood pressure above 90 mmHg when combined with 
other risk factors had a cumulative influence on arterial lumen narrowing. This effect 
however, did not occur independently. In addition to these findings, Shapiro et al (1990) 
have suggested that blood pressure elevations are detrimental to the integrity of the 
transplanted organ and contribute to considerable morbidity in the post-transplant 
population. Although the evidence to date is limited, it is possible therefore, that 
adequate blood pressure control may be of some assistance in the prevention of CAD 
following cardiac transplantation. 
Blood pressure elevations are a frequent occurrence following orthotopic heart 
transplantation. The exact prevalence is difficult to determine due to the lack of available 
data, the small sample size and varying definitions of hypertension used in the available 
studies. However, blood pressure elevations have been demonstrated in up to 90 per 
cent of cardiac transplant patients (Renuld et al 1989). The time course for the 
development of this disorder shows variation in the literature. Olivari et al (1989) for 
example, suggested that, at two weeks following transplantation 68 per cent of patients 
were hypertensive, whilst at six months the prevalence was 92 per cent. It is important to 
recognise however, that the investigators defined hypertension as a blood pressure above 
140 / 90 mmHg, a level below the currently accepted definition of hypertension. 
Ozdogan et al (1990) on the other hand reported that the probability of hypertension 
(blood pressure > 150/95 mmHg) was 52 per cent at one year, 67 per cent at two years 
and 73 per cent at three years, indicating that this disorder increases progressively with 
time. In addition, Shapiro et al (1990) demonstrated that the mean initial onset occurred 
at 50 days post-operative and ranged from one week to six months following 
transplantation, suggesting that the development of hypertension is highly variable 
amongst individuals following heart transplantation. 
A multitude of factors are thought to impact upon the development of hypertension in 
transplant recipients. Physiological changes following transplantation are thought to play 
a role. Denervation, which occurs as a consequence of transplanting the human heart 
has been shown in some studies to contribute to this problem via the loss of afferent 
receptors within the heart which influence blood pressure (Shapiro et al 1990). Post-
operative volume changes are thought to promote immediate post-transplant 
hypertension. However, this does not explain the long-term existence of blood pressure 
elevations. An alternative explanation which has been offered is the increased peripheral 
resistance noted in heart failure, persisting in the presence of a transplanted heart (Shapiro 
et al 1990). 
In addition to physiological changes, immunosuppressive protocols may also be 
inductive of hypertension. Cyclosporine is thought to be the major culprit in this 
process. The mechanism by which this immunosuppressant increases blood pressure is 
controversial. Regardless of this, there is little dispute that it plays a significant role in 
hypertension development. The nephrotoxicity of cyclosporine is well documented 
(Myers et al 1984; Martin et al 1987), thus the effects on renin and angiotensin activity 
make a likely contribution to hypertension (Shapiro et al 1990). This effect however, has 
been disputed in the literature, with some researchers reporting the absence of major 
abnormalities in the activity of these enzymes with cyclosporine administration (Bellet et 
al 1985). Furthermore, some studies have failed to find any association between 
cyclosporine dose and blood pressure, indicating that nephrotoxicity may be unrelated to 
this condition (Ozdogan et al 1990). An alternative explanation for the effects of 
cyclosporine come from animal studies which suggest that this immunosuppressant is a 
direct vasoconstrictor, thus a potential blood pressure elevator (Rego et al 1988). 
Although the mechanisms by which cyclosporine affects blood pressure remain unclear, 
it is evident that it plays a significant role in post-transplant hypertension. 
The finding that hypertension also occurs in transplant patients not receiving cyclosporine 
implies that other factors potentially contribute to this disorder (Ozdogan et al 1990). 
These factors may include recipient characteristics such as a predisposition to 
hypertension, age, family history of cardiovascular disease or recipient sex (Ozdogan et 
al 1990). The effects of donor characteristics however, have not been widely reported. 
Obesity may also influence hypertension development as it does in the general 
population. Olivan et al (1989) observed that normotensive patients had less post-
transplant weight gain than the transplant population as a whole. However, these 
difference failed to reach statistical significance. In addition, there is some evidence to 
suggest that corticosteroids play a role in the elevation of blood pressure through the 
effects on arteriole sensitivity and sodium retention (Shapiro et al 1990). However, few 
studies to date have investigated these effects. 
It is therefore evident that hypertension is a complication of cardiac transplantation which 
concerns a large proportion of this population. Although the effects of blood pressure 
elevations on long-term outcomes of heart transplantation have not been defined it is 
plausible that this disorder has adverse consequences for CAD development. 
Pharmacological management and careful patient monitoring are likely to assist with 
blood pressure control. Dietary and lifestyle factors such as weight reduction are 
additional modes of therapy with few adverse side effects, thus their role in both the 
treatment and prevention of this disorder is likely to be beneficial. 
2.6. DIETARY INTAKE 
2.6.1 Diet in Coronary Heart Disease 
Diet has been identified as a corner stone in both the prevention and treatment of 
cardiovascular diseases. Appropriate dietary modifications have been suggested to 
reduce the risk of coronary heart disease by up to 20 per cent in the general population 
(Gotto et al 1990). Decreased body weight, total cholesterol, LDL cholesterol, blood 
pressure, blood triglycerides as well as increased HDL cholesterol have been shown to be 
the result of dietary intervention (Schaefer et al 1981; Grundy and Denke 1990; Cheung 
et al 1994). Although estimates vary as to the effect of diet on reducing cardiovascular 
risk, it is generally agreed that it is a safe and effective means of heart disease prevention. 
Predominant dietary factors in coronary heart disease include fat, cholesterol, sodium and 
alcohol. Both total fat intake and fatty acid ratios are important in cardiovascular risk 
reduction. The proportion of total fat in the diet with respect to energy intake is 
associated with heart disease risk. This relationship, however, is not independent and is 
thought to be mediated through the effects of fat intake on body weight, and the 
association of a high fat intake with an increased intake of saturated fatty acids (Shrapnel 
et al 1992). 
The ratio of saturated, polyunsaturated and monounsaturated fatty acids is thought to be 
more influential. Diets high in saturated fat, through their influence on LDL and total 
cholesterol, have a significantly negative effect on heart disease risk (Keys et al 1986). 
This relationship is strong and independent (Kromhout et al 1989). The role of 
polyunsaturated fats is more controversial. The omega-3 polyunsamrated fatty acids have 
been shown to reduce post-prandial lipemia, serum triglycerides and the tendency to 
thrombosis (Mackness et al 1994; Zamperas et al 1994). Whilst omega-6 
polyunsaturated fats are thought to have an independent cholesterol lowering effect 
(Shrapnel et al 1992). However, detrimental effects of polyunsaturated fat consumption 
have also been suggested (Hodgson et al 1993). Monounsaturates, once thought to have 
a neutral effect on serum cholesterol, have been shown to reduce LDL cholesterol when 
substituted in the diet for saturated fats (National Health and Medical Research Council 
1992). More recently, trans fats, resulting from the hydrogénation of vegetable oils, 
have come into focus as an additional dietary consideration. Evidence however, suggests 
that the effects of these fats on cholesterol levels are less than saturated fatty acids found 
in animal products (Zock and Katan 1992). Consequently, dietary modifications of fatty 
acids plays an important role in heart disease prevention. 
The benefits of dietary cholesterol reduction have been met with much controversy. A 
large number of studies investigating the relationship between cholesterol intake and heart 
disease risk have produced inconsistent findings. However, it is thought that dietary 
cholesterol may increase the risk of heart disease in sensitive individuals who cannot 
down-regulate endogenous cholesterol synthesis in response to exogenous intake 
(Shrapnel et al 1992). Hence modifying dietary cholesterol intake may be advantageous. 
The intake of dietary sodium has also been related to the risk of cardiovascular diseases 
(Elmer et al 1991). A high salt intake, in excess of physiological requirements, is 
implicated in the development of hypertension. It is thought that this effect may be even 
stronger in a subset of individuals who are sensitive to the effects of sodium (Shrapnel et 
al 1992). As a total population approach to the prevention of cardiovascular diseases, 
sodium restriction is controversial (Pecker and Laragh 1991). However, to date, there is 
little evidence of adverse consequences of dietary sodium reduction (Elmer et al 1991). 
Some researchers have even suggested that population based sodium restriction to 50 to 
100 mmol daily may reduce the population mean blood pressure and reduce requirements 
for anti-hypertensive pharmacological treatment (Beilin 1992). It is likely therefore, that 
sodium restriction is a valid dietary action, particularly in high risk individuals. 
Alcohol intake, depending on the level of consumption, can be detrimental or possibly 
beneficial to heart disease risk. Excessive alcohol consumption has been observed to 
increase serum triglycerides and blood pressure thus heart disease risk (Ahlawat and 
Siwach 1994; Stamler et al 1991). In addition, heavy drinkers may be at increased risk 
of other cardiovascular consequences including sudden cardiac death and cerebrovascular 
accidents (Lester 1994). On the other hand, small quantities of alcohol, consumed on a 
regular basis may offer a protective cardiovascular effect via its influence on HDL 
cholesterol and platelet reactivity (Renaud and de Lorgeril 1992; Ganziano et al 1993). 
Although it remains controversial as to whether the high density lipoprotein cholesterol 
sub-class elevated by alcohol actually confers any cardiovascular benefits (Diehl et al 
1988). As a result, reduced alcohol consumption is recommended. 
An increased intake of carbohydrates and dietary fibre is recommended as an adjunct to 
healthy heart diet therapy. The benefits of such a dietary pattern include reduction in fat 
intake because of dietary substitution with these nutrients. Whilst fibre, particularly the 
soluble variety has been shown to reduce total and LDL cholesterol through faecal bile 
losses (Anderson et al 1991). Thus the benefits of increasing both fibre and carbohydrate 
intake are evident in both heart disease prevention and treatment. 
Diet clearly plays a role, both in the establishment and prevention of coronary heart 
disease in the general population. Current dietary recommendations advocate a total fat 
intake of less than 30 per cent of energy, with saturated fat accounting for less than 10 
per cent of total energy intake. Sodium intake is recommended to be less than 100 mmol 
per day and cholesterol below 300 milligrams per day, whilst alcohol intake should not 
exceed 20 grams daily for women and 40 grams each day for men. In addition, fibre 
intake is encouraged (Stewart 1990; Thomas 1994). Ideally, dietary intervention should 
achieve a body weight appropriate to height (as indicated by BMI), blood cholesterol 
levels below 5.5 mmol/L, triglycerides less than 1.8 mmol/L, and diastolic and systolic 
blood pressure less than 90 and 150 mmHg respectively (Curtin University of 
Technology 1992; Dwyer 1995). 
2.6.2 Diet in Cardiac Transplantation 
In heart transplant recipients, the role of diet in the aetiology of post-transplant CAD is 
not as clear. The influence of pharmacological, immunological and infectious factors in 
conjunction with a lack of available research, makes it difficult to ascertain the extent to 
which diet can be implicated in the establishment of, or assist in the prevention of 
cardiovascular complications. 
Nutrition care of the heart transplant patient generally occurs as a three step process. 
Prior to transplantation, patients often require intervention as a result of muscle wasting, 
hypermetabolism and protein and fat malabsorption (Kumar and Coulston 1983). 
Immediately post-transplant, patients may exhibit anorexia and post-operative catabolism 
that warrants supplemental or enteral nutrition (Frazier et al 1985). However, more 
frequently, appetite and nutritional status are significantly improved (C. Rawcliffe; 
Personal Communications 1995). In the long term, the increased risk of developing 
cardiovascular complications is an indication for nutrition intervention (Poindexter 1992). 
Pre and immediate post-operative dietary requirements, considerations and interventions 
are beyond the scope of this study. This review is concerned specifically with the long 
term dietary management of heart transplant recipients. 
At St. Vincent's Hospital, long term nutritional management involves assessment and 
education by a Clinical Nutritionist. Dietary recommendations are based on a healthy 
heart diet. This includes, less than 30 per cent of energy from fat, less than 10 per cent 
of energy from saUirated fat, less than 300 milligrams of cholesterol per day, an increased 
dietary fibre intake and no added salt. These dietary guidelines are compatible with those 
recommended by the National Heart Foundation for the prevention of cardiovascular 
disease in the general population (Shrapnel et al 1992). 
Similar guidelines exist in other heart transplant centres. Approximately 80 per cent of 
transplant centres in the United States include a dietitian as a member of the cardiac 
support team. The most common long term post-transplant dietary recommendation is a 
2-4 gram sodium restriction, low fat, low cholesterol diet. This is advocated in 30 per 
cent of transplant centres. However, often, a more stringent diet which includes 
restricted dietary fat to less than 30 per cent of energy, restriction of saturated fat to less 
than 7 per cent of energy and dietary cholesterol intake of less than 200 milligrams per 
day is recommended (Moore et al 1991). 
The few studies reporting on the diet of post-transplant patients suggest that the dietary 
intake of this population generally complies with recommendations. Total fat intake has 
been reported to be approximately 33 per cent of energy in one French study (Salen et al 
1994). This is similar to the reported intakes of the Australian population (Baghurst et al 
1994). In the same study, saturated, polyunsaturated and monounsaturated fat accounted 
for 12, 7 and 11 per cent of energy respectively. Alcohol and fibre intakes in this 
population were reported to be low. The researchers concluded that compliance with the 
dietary advice provided by doctors or dietitians was high in the post-transplant population 
(Salen et al 1994). The results of this study, however must be interpreted with care as 
the twenty-four hour recall as used to assess dietary intake does not account for intra-
individual variation in dietary intake (Cameron and van Staveren 1988). Whilst cultural 
factors reduce the comparability of these findings with the Australian population. 
In comparison, subjective assessments of dietary intake as undertaken in some studies 
indicate that compliance with dietary recommendations is generally sub-optimal. Keogh 
(1987), in studies on hyperlipidaemia, suggested that compliance with low fat, low 
cholesterol dietary advice was often poor. This claim was based upon the high incidence 
of obesity and hyperlipidaemia in this population and was not substantiated with evidence 
regarding actual dietary intakes. Keogh also noted in her study, the possible role of 
lifestyle factors in reducing cardiovascular risk and the need for more stringent efforts for 
weight control, hence dietary intervention, in the transplant population. 
The degree to which current recommendations for the long term management of heart 
transplant recipients reduce cardiovascular risk, is not known. In renal transplant 
patients, who tend to have similar clinical profiles, evidence suggests that diet therapy is a 
safe and effective means of treatment. Dietary modifications including a reduction in 
saturated fat, cholesterol, simple sugars and alcohol intake have been associated with 
significant reductions in plasma cholesterol and body weight in this population (Disler et 
al 1981). Little has been reported on the relationship between these known risk factors 
and dietary intakes in the heart transplant population. 
Ragsdale (1987) has attempted to show improved nutritional status as a result of dietary 
intervention by comparing nutrition intervention in the initial stages of a post-transplant 
nutrition program, with later more stringent interventions. The first 10 heart transplant 
recipients at the Indiana Methodist Hospital were placed on a type IIA 
hyperlipoproteinemia (less than 300 milligrams of cholesterol), restricted simple sugar, 
and 2 - 4 gram sodium-restricted diet. Dietary follow up in these patients was limited. 
Of these patients, five gained 20 kilograms or more above their pre-transplant weight and 
four died as a result of accelerated CAD within eighteen months. Since the initiation of a 
nutrition education program which emphasised less than 25 per cent of energy from fat, 
10 per cent monounsaturated fat and 10 per cent saturated fats, as well as regular dietetic 
intervention, a larger proportion of patients were living beyond one year. At the same 
time, the incidence of obesity and mortality from CAD was reduced. These 
improvements were attributed to changes in medications, improved dietary monitoring 
and increased patient and family involvement with dietary modifications. Although this 
study suggests that dietary intervention may play a role in improving the long term 
cardiovascular health of transplant recipients, the statistical significance of any changes 
and the extent to which improved health outcomes were related to dietary intervention 
were not reported. 
There is some evidence that a Mediterranean style of eating may be effective in the long 
term management of heart transplant patients. The Mediterranean diet, as popularised by 
The Seven Countries Study is low in total fat, and saturated fat and high in mono-
unsaturates, and is associated with a low cardiac mortality rate in the general population 
(Kromhout et al 1989). In heart transplant recipients, the possible benefits of consuming 
such a diet include a reduction in LDL cholesterol as a result of a low saturated fat intake, 
reduced body weight occurring in conjunction with less calories from fat, and a reduced 
oxidation of lipoproteins to foam cells as a result of the effects of oleic acid, a mono-
unsaturate (National Health and Medical Research Council 1992; Kromhout et al 1989). 
Salen et al (1994) in a dietary intervention study evaluated the effects of the 
Mediterranean diet on cholesterol levels in post-transplant recipients. Forty one 
transplant recipients with hypercholesterolaemia were studied for an eighteen month 
period. They were provided with diet counselling to reduce total fat, saturated fat and 
polyunsaturated fat to less than 30, 10 and 6 per cent of total energy respectively. 
Saturated and polyunsaturated fats in the diet were replaced with monounsaturates 
including olive and rapeseed oils. Participants were advised to avoid rich sources of 
polyunsaturates, to select low fat dairy products, lean meats and increase fruit, vegetable 
and cereal consumption, as well as drink moderate amounts of wine during meals. 
The mean dietary intake one year after initial counselling was significantly lower in total 
calories and saturated fat. Intakes of polyunsaturates, cholesterol and total fat were 
lower, whilst monounsaturated fat intake was higher, these differences however, were 
not statistically significant. The biochemical profile of participants showed significantly 
reduced total and low-density lipoprotein cholesterol after diet modification. Body 
weight did not significantly differ, nor did high density lipoprotein cholesterol levels or 
arterial blood pressure. Although immunosuppressive therapy was progressively 
reduced during the period of the study, there were no significant changes in blood 
pressure or blood triglycerides. Hence, it was concluded that changes in the biochemical 
profile of participants was the result of dietary intervention. The potential role of diet as 
an alternative to pharmacological treatment in these patients is therefore promising. 
However, the impact of dietary intervention on long term survival could not be 
determined due to the short time period of the study and absence of a control group. 
The need for a large controlled study to confirm these findmgs is warranted. 
The benefits of dietary sodium restriction in the post-transplant period have also been 
implied. Sodium intake has been linked with hypertension in epidemiological studies, 
clinical trials and animal studies (Shrapnel et al 1992). Singer et al (1994) found similar 
results in the heart transplant population. In a study on twelve transplant recipients, it 
was reported that a sodium intake of ten mmol per day substantially reduced systolic 
blood pressure, whilst a 350 mmol per day intake was associated with increased blood 
pressure (Singer et al 1994). The effect was similar to that found in non-transplant 
recipients with essential hypertension. The potential for sodium restriction as a non-
pharmacological alternative to the treatment of post-transplant hypertension is therefore 
evident. However, it must be noted that, in real life, the 10 mmol daily intake of sodium 
on the low salt diet as implemented in the above mentioned study is largely unachievable 
and less than recognised human physiological requirements (National Health and Medical 
Research Council 1991). Further studies are required determine the role of currently 
recommended level of sodium intake in blood pressure control in this population. 
The possible role of a multitude of factors in post-transplant CAD, makes the contribution 
of diet in both its development and treatment largely controversial. Other studies 
supporting those of Salen et al (1994) and Singer et al (1994) are limited. There is 
however, some contradictory evidence which suggests that dietary intervention has little 
effect on reducing body weight, serum lipids or blood pressure in the post-transplant 
recipient (Eich et al 1990). Ballantyne et al (1992) in a six year follow up of transplant 
patients, reported that the American Heart Foundation Step One Diet had little effect on 
reducing serum cholesterol, triglycerides or LDL cholesterol levels. However, it should 
be noted that compliance with the dietary recommendations was not measured in this 
study. Hence, these results may not reflect the true advantages of dietary intervention. 
The role of dietary intervention has also been questioned by Becker et al (1988). They 
found no correlation between LDL cholesterol, total cholesterol or triglyceride levels and 
dietary fat intake. As a result it was concluded that low levels of dietary fat and 
cholesterol demonstrate little effect on serum lipids. Again caution must be taken in the 
interpretation of these results. Firstly, the actual dietary fat intake of the sample was not 
reported in the study. The results therefore rely on the researchers assessment of what 
constitutes a low fat diet. In addition, a similar dietary fat questionnaire as that used to 
measure intake has recently been reported to lack the sensitivity and specificity to be used 
as a single assessment method (Caan et al 1995). Conclusions regarding dietary intake 
and contribution to CAD, therefore remain controversial. 
Cardiac transplant patients are clearly at high risk of developing long term cardiovascular 
complications. Although diet has been established as a key factor in the coronary heart 
disease seen in the general population, risk factors in heart transplant recipients are not as 
clearly defined. Further investigation into the effectiveness of diet therapy, the dietary 
intake of this population and the optimum dietary recommendations is needed to assist in 
the prevention and non-pharmacological management of post transplant CAD. 
2.7 MULTIPLE CARDIOVASCULAR RISK FACTORS 
AND CAD DEVELOPMENT 
The evidence from the literature to date clearly suggests that the role of conventional 
cardiovascular risk factors in the development of CAD following heart transplantation 
remains highly controversial. Although the underlying cause of CAD in the cardiac 
transplant recipient has yet to be determined, evidence suggests that a combination of 
immunological and non-immunological factors influence CAD development. In support 
of this hypothesis, there is considerable evidence that risk factors including 
hyperlipidaemia, obesity, hypertension and diabetes mellitus, in conjunction with dietary 
and lifestyle factors contribute to this anomaly. 
Although each of the risk factors have been discussed separately in this report, the 
multifactorial nature of this disorder is noteworthy. Obesity for example is likely to affect 
other risk factors such as diabetes and hypertension. Whilst dietary intake has multiple 
consequences for cardiovascular profile. It has been suggested in some studies that the 
affect of these risk factors is additive on CAD development. Winters et al (1990) 
demonstrated that percentage luminal narrowing was increased with the successive 
addition of each conventional cardiovascular risk factor in cardiac transplant recipients. 
In patients with a BMI >27, they reported a rise in luminal narrowing from 66 to 80 per 
cent. This is similar to findings in the general population which have suggested that the 
existence of multiple risk factors has adverse consequences for cardiovascular profile. 
Clearly, an effective means of prevention would be beneficial to both quality of life and 
survival in this population. However, inconsistencies in the literature to date, warrants 
further research to investigate the underiying aetiology, prevalence and preventative 
options for this major limiting factor in the long term survival of cardiac transplant 
recipients. 
2.8. METHODOLOGY 
2.8.1 Body Weight Assessment 
Body weight can be measured using a number of different anthropometric assessment 
methods. In the present study, body mass index, waist-to-hip ratio and waist 
circumference have been selected as determinants of cardiovascular risk. 
In clinical practice, the body mass index (BMI) is the most frequently defined measure of 
overweight and obesity. BMI is a measure of the ratio of weight (kg) to height (m)2 and 
is useful for comparing body weights between persons of differing height. A BMI in 
excess of 25 is constitutes overweight, whilst that greater than 30 is characteristic of 
obesity (Bray 1985). These classifications are shown in table (1) below. 
BMI CLASSIFICATION 
<19 Underweight 
20-25 Healthy Weight 
26-30 Overweight 
31-40 Obese 
>40 Morbidly Obese 
Table 2.7.1 Classifications of Body Weight based on BMI 
(Adapted from Bray 1985) 
The BMI is advantageous as a measure of body weight in that it is easy to calculate and 
provides a simple total body weight classification criteria which can be used to assess 
potential health risks (Bray 1985). However, this technique of anthropometric 
assessment provides little information on the distribution of body fat and there is some 
evidence that BMI is not predictive of cardiovascular risk (Loos and Halais 1991; 
Hodgson et al 1994). Some researchers have also suggested that the BMI misclassifies 
obese patients when compared with measures of body fat (Hortobagyi et al 1994). Thus 
methods to assess body composition may provide a more useful indication of 
cardiovascular risk than total body weight. 
One of the most commonly employed methods to determine the site of fat deposits is the 
waist-to-hip ratio (WHR). The WHR assessment technique involves measuring both the 
waist and hips with a non-stretchable tape measure and calculating the resultant ratio. 
The validity of this method for determining body fat distribution has been reported by 
Loos and Halais (1991) who established that this measure was a valid means of 
identifying increased cardiovascular risk and increasing abdominal fat deposition. Ross 
et al (1992) on the other hand, compared similar anthropometric variables with magnetic 
resonance imaging and concluded that WHR was not a good indicator of visceral 
adiposity. 
The inconsistencies in the literature on WHR clearly make it difficult to assess the validity 
of this method for body fat assessment. It is likely that the wide variation in WHR 
methodologies contributes to methodological problems. To date, over 18 different sites 
for measuring the waist and hips have been identified (Loos and Halais 1991) each which 
been reported to significantly alter the WHR (Alexander and Dugdale 1992). Houmard et 
al (1991) have attempted to clarify this issue by comparing five different sites for WHR 
assessment with metabolic variables. The results of which suggest that measures at 
minimal waist / maximal hips, umbilicus / maximal hips, umbilicus / greater trochanters 
and umbilicus / iliac spine are most strongly associated with indices of lipid and 
carbohydrate metabolism. Thus it is possible that a number of sites may be utilised to 
determine the degree of cardiovascular risk. 
A potential problem in WHR assessment is the use of different cut-off points to indicate 
cardiovascular risk. Some researchers suggest that a WHR of <0.9 for males and <0.8 
for females are the most desirable for cardiovascular health (Egger 1992). Elsewhere 
however, levels of 0.95 and up to 1.0 have been suggested for males and 0.85 and 0.75 
for females (Loos and Halais 1991; Despres et al 1992). Clearly, the use of these cut off 
points is likely to be dependant on the chosen site and will ultimately affect the degree of 
cardiovascular risk. The cut-off points of 0.9 for males and 0.8 for females have been 
shown by several researchers to correspond with cardiovascular risk at the site of the 
umbilicus / iliac spine (Alexander and Dugdale 1992; Egger 1992). 
The reliability of WHR assessment technique appears to be satisfactory. Several recent 
studies have shown that repeated measures produce similar results. Rasmussen et al 
(1993), demonstrated that intra-observer variation was low in the measurement of WHR 
and concluded that repeated measurements were not necessary in clinical trials. Other 
researchers have demonstrated that multiple measures differ by up to 0.62 cm for the 
waist and 1.24 cm for the hips. As a result, WHR variation is 0.02 (Alexander and 
Dugdale 1992). Similarly, Loos and Halais (1991) reported the mean difference between 
two measures of WHR to be less than 1 per cent. 
More recently, waist circumference has been identified as a better indicator of abdominal 
fat distribution and consequent cardiovascular risk. Pouliot et al (1994) compared 
visceral adipose tissue using computer tomography with measures of waist 
circumference, abdominal sagittal diameter and WHR. They found that waist 
circumference measures >100 cm and sagittal diameter >25 cm were the most likely to be 
associated with the metabolic disturbances which affect cardiovascular risk. This is 
supported by more recent studies from Lean et al (1995) who demonstrated that waist 
circumference was useful in identifying increased cardiovascular risk, independent of 
WHR. Waist circumference could therefore be utilised as either an indépendant or 
additional measure of body fat distribution. 
2.8.2 Dietary Intake Methodology 
The diet history, as described by Burke (1947) is a method of measuring the usual dietary 
intake of individuals. This process involves an extensive interview to obtain information 
regarding foods consumed and frequency of consumption and methods of preparation. 
As with other means of dietary assessment, there are both advantages and limitations to 
using this method as a tool in research. 
The diet history is advantageous in that it requires little time commitment from 
respondents, as a result, participation rates may be increased (Cameron and van Staveren 
1988). As the focus of this method is on usual it also allows for the assessment of 
intake over a longer period than other methods (eg. 24 hour recall, 3 day food records). 
In addition, it allows for exploration of food preparation techniques and probing for 
further details regarding intake (Thompson and Byers 1994). 
Major limitations of the diet history include the large subjective component required in 
estimating intake, as participants are required to make judgements regarding usual foods 
and serve sizes. Thus actual intake is subject to possible misinterpretation. The diet 
history is also problematic in the fact that data collection requires participants to have a 
usual dietary pattern. As a result, individuals with inconsistent intakes cannot be 
included in analysis. In addition, the usual aspect of this method, frequently results in 
omission of less frequent, but possibly important dietary contributions (Freudanheim 
1993). 
The validity of the diet history method is subject to some controversy. A number of 
researchers have found that nutrient intakes tend to be over estimated when compared 
with other methods (Nes et al 1991). Whilst Black et al (1993), have reported that 
weight-conscious individuals may actually underestimate usual intake with this method. 
On the other hand, some have suggested that an in depth history is a relatively valid 
means of dietary assessment (Freudanheim 1993). Whilst, other researchers have 
reported a correlation between this method and biochemical indicators (van Staveren et al 
1985). However, this has not been consistently demonstrated. 
Overall, the diet history method, as with other means of dietary intake assessment is 
subject to inaccuracies. As a result, it is recommended that nutrient intakes be interpreted 
as relative rather than absolute. To accommodate this in research, Bourke (1947) has 
recommendaed that individuals be ranked into high, moderate and low classifications for 
the range of nutrients examined. As a result, using a range of intakes should reduce 
inaccuracies evident with this measurement technique. 
3. METHODS 
3.1 Setting 
This project was undertaken at St. Vincent's Hospital (SVH), Sydney from August to 
November 1995. At the time of writing, SVH was a 400 bed teaching hospital and the 
only institution performing cardiac transplantation within New South Wales. 
3.2 Sample 
The sample was selected from the St. Vincent's Hospital heart transplant population who 
had received a successful orthotopic transplant within the past 12 to 24 months. This 
time frame was selected because there is evidence to suggest that risk factors for heart 
disease occur within the first year post-transplant. In addition, biochemical and 
anthropometric indicators are regularly monitored during this period and are therefore 
available for analysis. 
Fifty four orthotopic heart transplants were performed at SVH from July 1993 to 
November 1994. Of these, eight patients had died, leaving of 46 transplant recipients. 
The small size of the transplant population required all patients who met the inclusion 
criteria to be contacted for participation. 
3.3 Inclusion Criteria 
For inclusion in the study, the patients had to meet the following criteria: 
i) Successful orthotopic heart transplant within past 12 to 24 months 
ii) Over 18 years of age 
iii) No other medical condition that may affect nutritional stams (eg. liver or renal disease, 
cancer) 
iv) No special physiological requirements (eg. pregnancy) 
3.4 Participant Contact 
Patients who met the above criteria were selected from SVH records. Each person was 
sent a letter explaining the aims and objectives of the project and the nature and extent of 
participant involvement (refer to appendix 11.2). This was followed up with a telephone 
call to each patient. A convenient date (between August and October 1995) and venue 
was arranged with those who agreed to participate. 
3.5 Ethical Issues 
Approval was obtained from the SVH and University of Wollongong Ethics Committee's 
(refer to appendix 11.1). Informed consent was obtained by a written consent form, a 
copy of which was retained by both the researcher and participant (Refer to appendix 
11.3). Each participant was identified by their hospital transplant number to ensuring 
confidentiality. Information which identified participants was not removed from SVH. 
3.6 Data Collection 
The study involved two type of data collection - retrospective information from SVH 
medical records and information provided by the participant. These are described below. 
Demographic Data 
Da t̂a describing the characteristics of each participant, including age, sex, initial 
diagnosis, medication protocols and waiting period for transplantation was obtained from 
SVH medical records. 
Anthropometric Data 
Recent / current body weight was obtained from SVH outpatient medical notes and 
transplant records. If weight was not recently recorded this was obtained by weighing 
participants. Pre-transplant body weight, weight at 1, 3, 6, 12, 18 and 24 months post-
transplant (as appropriate) was obtained from SVH pre-transplant assessment clinic and 
outpatient medical notes. Participants were weighed on the same set of scales at each 
time interval. However, a number of participants were weighed on a smaller set of scales 
if their recent weight had not been recorded. The same set of scales was used for each of 
these participants. Weight was recorded to the nearest 0.5 kg. Height was obtained 
from SVH pre-transplant assessment clinic records. The accuracy of this information 
was verbally confirmed with participants. Height was recorded to the nearest 1.0 cm. 
Waist to hip ratios were determined by measuring participants waist and hips with a 
plastic tape measure. Waist measurement was determined at the level of the umbilicus, 
whilst hips were measured at the superior iliac crest. All measurements were taken while 
participants were lightly clothed and upright with arms at their sides. Each site was 
measured twice and the average of the two readings was recorded. 
Dietary Intake 
To obtain information regarding usual dietary intake, participants were each interviewed 
for approximately one hour. A modified version of Burkes original diet history was the 
selected method (Burke 1947). The aim of the diet history was to quantify usual dietary 
intake and derive qualitative information about eating behaviours. Participants were 
asked to describe their usual dietary intake in as much detail as possible. A food 
frequency questionnaire was used as a crosscheck and to further quantify diet history 
data. The three day food record as used by Burke was not included due to time 
constraints. Food models, standard measures and participant drawings were used to 
quantify serve sizes. 
Participants were also asked a series of additional questions. This included describing 
methods of food preparation, use of convenience and takeaway foods, and brands and 
varieties of food products consumed. Each participant was also asked to rate present 
appetite (poor, good, excellent), changes in appetite since transplantation (increased, 
decreased, no change) and noticeable changes in weight since transplantation (increased, 
decreased, no change). Finally, to determine current level of physical activity. 
participants were asked if they engaged in any regular exercise and if yes, the duration 
and frequency of activity. 
Biochemical Indicators 
Total cholesterol and blood triglyceride levels were obtained from SVH outpatient 
medical notes and transplant records. These measurements were obtained using standard 
hospital collection and analysis procedures. This data was recorded at pre-transplant, and 
1, 3, 6, and 12 as well as 18 and 24 months post-transplant (where applicable). 
Blood Pressure 
Blood pressure measurements were obtained from SVH outpatient medical notes and 
transplant records. This data was recorded at pre-transplant, and 1, 3, 6, and 12 as well 
as 18 and 24 months post-transplant (where applicable). The administration of anti-
hypertensive medications or a diastolic blood pressure exceeding 95 mmHg were 
considered to constitute hypertension. The degree of blood pressure control over time 
was noted for this population. 
Diabetes Mellitus 
The presence or absence of diabetes mellitus was also noted, as was mode of control (eg. 
diet, oral hypoglycaemic agents, insulin) 
3.7 Data Analysis 
The collected data was analysed as follows: 
Demographic Data 
The participants age, sex, medications and initial diagnosis were used to describe the 
characteristics of the sample. Descriptive statistics were used to provide this information. 
Cholesterol Levels 
Cholesterol levels were analysed at pre-transplant and 1,3,6,12,18 and 24 months post-
transplant using an analysis of variance (ANOVA). A t-test was used to determine any 
significant changes between each increment. The proportion of patients with 
hypercholesterolaemia at each point in time was also noted. 
Triglyceride Levels 
Changes in triglyceride levels were described where available. Due to missing data, these 
were not statistically analysed. 
Body Weight 
Weights and heights were converted into the Body Mass Index (BMI). The BMI of 
participants was analysed at pre-transplant and 1,3,6,12,18 and 24 months post-
transplant using an analysis of variance (ANOVA). A t-test was used to determine any 
statistically significant changes at each increment. Average weight gain at each period 
and the proportion of patients in the underweight, healthy weight, overweight and obese 
categories of the healthy weight range were described for the group. 
Waist-to-Hip Ratio 
The Waist-to-Hip ratio was used to identify the occurrence of abdominal obesity in the 
post-transplant population. The mean ratios were compared to the recommended values 
of 0.80 for females and 0.90 for males. A t-test was used to determine any statistically 
significant differences. 
Blood Pressure 
Diastolic and systolic blood pressures were recorded at 1,3,6,12,18 and 24 (where 
applicable) months post-transplant and analysed using an analysis of variance (ANOVA). 
The proportion of patients with hypertension and degree of blood pressure control was 
noted over time. 
Diabetes Mellitus 
The occurrence of diabetes and mode of control were described for this population. 
Dietary Intake 
Dietary intake data was analysed quantitatively for total fat, saturated, monounsaturated 
and polyunsaturated fat, carbohydrate, protein, fibre, alcohol, cholesterol and sodium 
using the Diet Version 2.05 ( Xyris Software, Aust. Pty. Ltd. 1989) nutrient analysis 
program. Dietary intake data was compared to the current nutritional recommendations 
for heart transplant recipients. A t-test was used to determine the extent to which the 
mean intake for this population differs from these recommendations. Transplant 
recipients were ranked into categories according to low, medium or high levels of dietary 
intake for the analysed nutrients. 
4. RESULTS 
4.1 Patient Characteristics 
Of the 46 patients contacted, 17 were excluded from the study. Two of the patients had 
developed chronic renal failure, one had liver disease, one was less than 18 years of age, 
five lived interstate and were not attending SVH during the period of the study and eight 
were not able to be contacted. Of the remaining 29 patients, two declined to participate. 
The remaining 27 patients made up the study population. 
Table (1) lists the demographic characteristics of the patient population including age, 
sex, time since transplantation and pre-transplant waiting period. 
Variable Mean ±SD Range 
Age (years) 48.7 ± 7.9 (36 - 66) 
Sex Male: 23 
Female: 4 
Post-transplant Period 
(months) 
17.7 ± 4.67 (11-25) 
Waiting Period 
(days) 
137 ± 162.8 (1 - 546) 
Table 4.1: Characteristics of the patient population (N= 27) 
Age was recorded as that at time of participation in the study. The age range of 
participants was from 36 to 66 years, with mean of 48.7 years. Time since 
transplantation was also recorded at time of participation. The post-transplant period 
ranged from 11 to 25 months with a mean of 17.7 months. This deviation from selection 
criteria is the result of participant availability. There were more males than females 
participating in the study, with a male to female ratio of approximately 6:1. This is 
similar to the pattern seen in the total transplant population. Mean waiting period for 
transplantation was 137 days. Waiting time ranged from one to 546 days, depending on 
the availability of a of suitable donor. 
The pre-operative diagnoses for the study population are shown in Table 4.2. The most 
frequent diagnosis requiring transplantation was idiopathic cardiomyopathy or disease of 
the myocardium of unknown cause. Second to that was ischaemic heart disease, 
followed by valvular myopathy. Less frequent diagnoses included myocarditis, 
congenital heart disease and periparmm myopathy. 
Diagnosis Number 
Idiopathic Cardiomyopathy 13 
Ischaemic Heart Disease 9 
Valvular Myopathy 2 
Myocarditis 1 
Peripartum Myopathy 1 
Congenital Heart Disease 1 
Table 4.2: Pre-operative diagnosis of heart transplant recipients (N=27) 
All participants in this study were receiving triple-drug immunosuppression with 
prednisone, azathioprine and cyclosporine. Two participants were also receiving Adifax, 
an appetite suppressant, at the time of the study. 
4.2 Lipid Levels 
Hyperlipidaemia was defined as a serum cholesterol exceeding 5.5 mmol/litre, 
triglyceride levels greater than 1.8 mmol/litre or by the administration of lipid lowering 
agents. Prior to transplantation, 30 per cent of patients displayed hyperlipidaemia. At 
three months this increased to 44 per cent and at twelve months 41 per cent of transplant 
recipients were hyperlipidaemic. Figure 4.1 shows these results. 
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Figure 4.1: The frequency of lipid elevations following cardiac 
transplantation 
Mean total cholesterol levels were found to differ over time with an analysis of variance 
(ANOVA). A t-test was performed to test the significance of any differences at each 
interval in time. Prior to transplantation the mean cholesterol level was 4.4 i 1.3 
mmol/litre. At three months post-transplant, this increased significantly (t=-2.86 p<0.01) 
to 6.1 ± 1.6 mmol/litre. Over time, cholesterol remained elevated at a mean of 5.8 ± 1.1 
mmol/litre, 5.5 ± 0.8 mmol/litre and 5.5 ± 0.95 mmol/litre at six, twelve and eighteen 
months respectively. However, no further significant increases in cholesterol occurred 
after this time. In addition, the mean cholesterol for the four patients at 24 months post-
transplant was 5.3 mmol/litre. Figure 4.2 represents these results. 
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Figure 4.2 : Changes in total cholesterol over time in cardiac transplant 
recipients 
Triglyceride levels over time, were not readily available for all patients. Statistical 
analysis of these results was therefore not performed. Figure 4.3 below shows a trend to 
increasing triglycerides at 3 months post-transplant, with a progressive decline over the 
following months. 
5 T 
J 
'o 
B 
00 (D 
'C 
CJ 
'C 
H 
s 
Ui (L> C/D 
3 --
1 --
0 -L 
Pre 6 Months 12 Months 18 Months 
Months Post-Transplant 
Figure 4.3: Changes in triglyceride levels over time in cardiac transplant 
recipients 
4.3 Body Weight 
Participants were classified as being underweight, healthy weight, overweight or obese 
as calculated by BMI. The proportion of heart transplant patients in the overweight and 
obese categories of the healthy weight range increased with time from one month post-
transplant. Prior to transplant, 44 per cent of patients were above the desirable weight for 
height, at one month post-operative, this decreased to 22 per cent of patients. After this 
time the number of overweight and obese patients increased to 52 per cent at three 
months, 56 per cent at six months and by twelve months post-transplant, 56 per cent of 
recipients were overweight, with one third of these being classified as obese. The 
number of patients in the underweight and healthy weight ranges showed a 
corresponding decrease with time. Refer to Figure 4.4. 
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Figure 4.4: Weight status of the post-cardiac transplant population over 
time 
Changes in body weight were evident over time with an analysis of variance (ANOVA). 
A t-test was performed to determine the significance of these changes. The mean body 
mass index for participants prior to transplantation was 24.7 ± 3.3. At one month post-
operative this decreased significantly to 23.9 ± 3.5 (t=3.18 p<0.01). A steady increase 
in body weight that was significant at each increment was evident from three months 
post-transplant, up to twelve months. At three months mean weight increased to 25.1 ± 
3.69 (t=-4.22 p<0.01), at six months weight increased again to 26.3 ± 3.49 (t=-5.08 
p<0.01) and at twelve months post-transplant, the mean BMI was significantly higher at 
27.1 ± 4.6 (t=-3.02 p <0.01). This is equivalent to a mean weight gain of 7.8 ± 7.42 
kilograms from pre-transplant to twelve months post-transplantation. Significant changes 
in weight were not evident again after this time. Figure 4.5 represents this data. 
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Figure 4.5: Changes in body mass index (BMI) over time in cardiac 
transplant recipients 
To determine any differences between post-transplant body weight and weight prior to 
the onset of cardiac failure, participants ranked their present weight as increased, 
decreased or no change when compared to pre-transplant usual weight. Seventy per cent 
of patients indicated that their weight had increased, 11 per cent said it had decreased and 
19 per cent reported that their current weight was comparable to healthy pre-transplant 
weight Refer to Table 4.3 below. 
Weight change Percentage 
No Change 19% 
Increased 10% 
Decreased 11% 
Table 4.3: Self-reported changes in usual weight 
following cardiac transplantation 
4.4 Body Fat Distribution 
Indicators of body fat distribution were measured at the time of participation in the study. 
These included waist-to-hip ratio (WHR) and waist circumference. A WHR exceeding 
0.90 for males, 0.80 for females and a waist circumference greater than 100 cm were 
considered to pose cardiovascular risk. The mean WHR for males was 1.01 ± 0.06. A 
t-test revealed that this was significantly higher than recommended (t=8.713 p<0.01). 
The mean WHR of 0.80 ± 0.06 for females did not indicate cardiovascular risk. Overall, 
88 per cent of the total transplant population displayed a WHR larger than desirable. The 
mean waist circumference was 100.7 ± 15.7 cm and 33 per cent of participants had a 
circumference measure greater than 100 cm. Table 4.4 below shows the mean, range and 
t-test values for these variables. 
Variable Meant SD Range Recom, P Value 
Waist Circumference 100.7 ± 15.7 85.0 - 132.5 < 100 cm NS 
Waist-to-Hip Ratio 
Males (N= 23) 1.01 ±0.06 0.94- 1.10 <0.90 p<0.01 
Females (N=4) 0.80 ±0.06 0.75 -0.89 <0.80 NS 
Table 4.4: Indicators of body fat distribution in male and female cardiac 
transplant recipients 
4.5 Diabetes Mellitus 
Post-transplant diabetes mellitus occurred in five (19%) of the twenty seven participants. 
Two participants (7%) also exhibited non-insulin dependant diabetes mellitus prior to 
transplantation which was evident in the post-operative period. Two of the patients were 
maintained on insulin, whilst the remaining five were controlled with sulphonylurea oral 
hypoglycaemia agents. 
4.6 Blood Pressure 
Hypertension was determined as a blood pressure exceeding 95 mmHg diastole or the 
administration of anti-hypertensive medications. At one month post-operative, 52 per 
cent of participants displayed hypertension. This increased to 60, 67 and 73 per cent at 
three, six and twelve months respectively. This is shown in figure 4.7 below. 
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4.6 Hypertension over time following cardiac transplantation 
Mean diastolic and systolic blood pressures for the post-transplant population are shown 
in figure 4.7. Blood pressure over time did not change significantly with an analysis of 
variance (ANOVA). At one month post-operative mean blood pressure for the group was 
79 / 127 mmHg. At three, six and 12 months these values were 85 / 132, 86 / 137 and 
83/ 134 mmHg respectively. Over time following transplantation, none of the transplant 
recipients displayed persistent uncontrolled hypertension. 
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4.7 Changes in mean blood pressure over time following cardiac 
transplantation 
4.7 Dietary Intake 
All heart transplant recipients had been seen by a dietitian in the post-operative period. 
Table 4.5 below shows the mean dietary intakes of total fat, saturated fat, protein, 
carbohydrate, fibre, cholesterol and sodium. A t-test was performed to compare nutrient 
intakes with current recommendations. 
Nutrient Mean + SD Recom. PValue 
Fat (% energy) 31.7 ±4.73 <30% <0.05 
Saturated Fat 
(% energy) 
11.1 ±3.01 < 10% <0.05 
Carbohydrate (% energy) 41.5 ±7.31 
55 - 60% <0.01 
Protein (% energy) 
21.8 ±3.78 15 - 20% <0.01 
Cholesterol (milligrams) 317 ± 157.0 < 300 mg 
NS 
Fibre 
(grams) 
31.1 ± 10.1 25 -30g -
Sodium (mmol) 
121.9 ± 36.5 40 - 100 mmol <0.01 
Table 4.5: Dietary intake of cardiac transplant recipients compared to 
recommendations 
Fat 
The mean intake of total fat was significantly higher than the current dietary 
recommendations (t=1.84 p<0.05). There was considerable variability in regards to fat 
intake. A low fat diet was considered to be <30 per cent contribution to energy, a 
moderate fat diet was between 30 to 35 per cent of energy and a high fat diet was at 
intakes above this level. The percentage of patients with low, moderate and high fat 
intakes was 37, 37 and 26 per cent respectively. The range of fat intakes is shown in 
figure 4.8 below. 
Saturated Fat 
The mean intake of saturated fat was 11.1 ± 3.01 grams per day. This was significantly 
higher than the currently recommended < 10% of energy (p< 0.05). Figure 4.8 shows 
the range of saturated fat intakes in transplant recipients. A low intake was regarded to be 
<10 per cent of energy as recommended, a moderate was from 10 to 15 per cent of 
energy and a high at intakes above this level. Thirty seven, 56 and 7 per cent of 
recipients respectively displayed intakes at these levels. 
Carbohydrate 
The mean carbohydrate intake of the transplant population was significantly lower than 
the currently recommended 55 to 60 per cent of energy (t=-9.78 p<0.01). The range of 
carbohydrate intakes is shown in figure 4.8 below. A low carbohydrate intake of <40 
per cent of energy was demonstrated in 44 per cent of transplant recipients. A moderate 
intake of 40 to 55 per cent of energy was found in 56 per cent of participants whilst no 
participants had a high carbohydrate intake (>55 per cent of energy) as recommended. 
Protein 
Protein intake of the transplant population contributed to a mean 21.8 per cent of total 
energy. This was significantly higher than the recommended 15 to 20 per cent 
contribution of protein to energy intake (t=2.50 p<0.01). The range of protein intakes is 
shown in figure 4.8 below. A low protein was regarded as <20 per cent of energy. This 
was demonstrated in 26 per cent of participants. Moderate intakes of 20 to 25 per cent of 
energy were found in 52 per cent, whilst 22 per cent displayed high intakes of >25 per 
cent of energy. 
Cholesterol 
The mean cholesterol intake for the heart transplant population was 317 mg per day. This 
was higher than the currently recommended 300 mg daily. However, the difference was 
not statistically significant. Cholesterol intake was rated as low, <300 milligrams (as 
recommended), moderate, 300 to 400 milligrams and high >400 milligrams daily. Low, 
moderate and high cholesterol intakes were found in 55, 30 and 15 per cent of 
participants respectively. Refer to figure 4.8. 
Fibre 
The mean fibre intake for the heart transplant population was 31.1 gram per day. This 
level meets the current recommendations for fibre. The range of fibre intakes, low (<20 
grams), moderate (20 - 30 grams) and high (>30 grams) were found in eight, 44 and 48 
per cent of participants respectively. This is shown in figure 4.8. 
Sodium 
The mean sodium intake for this population was 121.9 mmol daily. This was 
significantly higher than the currently recommended 40 to 100 mmol per day (t=2.82 
p<0.01). The range of intakes is shown in figure 4.8. A low intake was considered to 
be <100 mmol as recommended, this was evident in 29 per cent of transplant recipients. 
A moderate intake of 100 to 150 mmol was reported by 52 per cent, whilst intakes above 
this level were evident in 19 per cent of participants. Figure 4.8 shows these results. 
The salt (sodium chloride) avoidance practices of transplant recipients were also noted in 
the study. Table salt use was reported by 15 per cent of participants, the use of salt in 
cooking by 11 per cent and both practices by 7 per cent of transplant recipients. 
Alcohol 
Alcohol intake was classified as low, moderate or high risk based on National Heart 
Foundation guidelines (refer to appendix 11.5). Thirty seven per cent of transplant 
recipients reported that they were non-drinkers, the remaining 63 per cent were classified 
as low risk for alcohol intake. Refer to figure 4.8. 
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Figure 4.8: Classifications of dietary intake for selected nutrients in the 
post-cardiac transplant population 
Current Eating Pattern 
Seventy one per cent of heart transplant recipients said that they were currently following 
some kind of special diet. A low fat diet was the most frequent, followed by a reduced 
fat and salt diet. These results are presented in table 4.6 below. 
Diet Percent 
No special diet 29% 
Reduced fat 29% 
Reduced fat / salt 22% 
Diabetes Diet 10% 
Healthy Diet 10% 
Table 4.6: The usual eating behaviour described by cardiac transplant 
recipients 
Exercise 
Participants described exercise habits in terms of frequency, intensity and type of activity. 
At 12 to 24 months post-transplant, only 48 per cent of cardiac transplant recipients were 
exercising at the recommended level of 30 minutes duration, three times per week. The 
remaining participants were either exercising at a level below this or were sedentary. 
Appetite 
To determine possible factors which may mfluence dietary intake, participants were asked 
to rate their current appetite and any changes in appetite since transplantation. The 
majority of participants reported that their current appetite was excellent and that appetite 
had increased following transplantation These results are described in Table 4.7 and 4.8. 
Current Appetite Per cent 
Poor 4% 
Good 37% 
ExceUent 59% 
Table 4.7: Appetite at 12 - 24 months post-transplant 
as described by cardiac transplant recipients 
Appetite Changes Per cent 
Increased 81% 
Decreased 11% 
No Change 8% 
Table 4.8: Self reported changes in appetite following 
cardiac transplantation 
5. DISCUSSION 
Heart transplant recipients are faced with CAD as an ironic impediment to long term 
survival. Conventional cardiovascular risk factors potentially contribute to this disorder. 
This study was initiated to describe the cardiovascular profile of a healthy post-cardiac 
transplant population. Dietary intake was investigated to further describe cardiovascular 
risk and identify adherence with current nutritional recommendations. 
5.1 Lipid Levels 
Previous studies have demonstrated that elevations in plasma lipids occur frequently 
following cardiac transplantation and that these are strongly related to CAD development 
(Winters et al 1990; Barbir et al 1991; Eich et al 1991). In the present study, 41 per cent 
of transplant recipients displayed hyperlipidaemia at twelve months post-transplant, as 
evident by the administration of lipid lowering drugs or cholesterol / triglyceride levels 
above desirable ranges. The prevalence of lipid abnormalities in this study is lower than 
that suggested by other researchers. Rudas et al (1990) for example, reported that 83 per 
cent of cardiac transplant recipients manifested hypercholesterolaemia by one year post-
transplant. Similarly, Keogh et al (1988) found that 50 per cent of transplant recipients 
with underlying ischaemic heart disease and 33 per cent of those with diagnosed non-
ischaemic cardiomyopathy displayed cholesterol elevations beyond desirable levels. 
These inconsistencies can be attributed to several key differences in the research. Firstly, 
differing definitions of lipid elevations have been used by investigators. Rudas et al 
(1990) for example, used total cholesterol levels >5.2 mmol/ L to describe lipid 
elevations. Whilst Keogh et al (1988) considered a significant degree of 
hypercholesterolaemia to be total cholesterol >6.5 mmol/L. In this study, 
hyperlipidaemia was described as total cholesterol greater than 5.5 mmol/L or 
triglycerides >1.8 mmol/L. As a result of these varying definitions, the prevalence rates 
show obvious differences. In addition, differences in medication protocols between 
study populations (particularly lipid lowering agents), differences in sample sizes and the 
timing of post-transplant blood lipid measurements are likely to influence results. 
The prevalence of lipid abnormalities in this group is comparable to those found in the 
general population. The National Heart Foundation Risk Factor Prevalence Survey 
(1989) demonstrated that 47 per cent of males and 39 per cent of females had cholesterol 
levels exceeding 5.5 mmol/L. Whilst 17 per cent of males and 7 per cent of females had 
triglyceride concentrations of greater than 2.0 mmol/L. On the surface this may suggest 
that the cardiac transplant population are in fact no different from the Australian 
population in terms of this cardiovascular risk factor. However, considering the 
accelerated rate at which CAD often appears in transplant recipients and a primary 
background of cardiovascular complications, these patients are possibly at greater 
cardiovascular risk due to lipid elevations than the general population. Hence, cholesterol 
levels above desirable should be treated aggressively in the post-transplant period. 
The pattern of lipid abnormalities demonstrated in this study suggests that 
hyperlipidaemia develops immediately following cardiac transplantation. The 
development of serum cholesterol elevations occurred within the first three months post-
transplant. After this time and up to twelve months post-transplant, cholesterol levels 
remained at the currently recommended levels or slightly elevated. Other studies have 
demonstrated a similar time course for hypercholesterolemia. Both Stamler et al (1988) 
and Rudas et al (1990) found that total cholesterol elevations reached statistical 
significance at three months post-transplantation. After this time, some investigators 
have found that blood lipids continue to increase (Ballantyne et al 1987), whilst others, 
like that found in this study, have demonstrated that these biochemical indicators remain 
elevated throughout the post-transplant period without further significant increases 
(Becker et al 1988; Stamler et al 1988). 
Serial evaluations of triglyceride levels in this study showed a similar pattern of post-
transplant elevation. Inconsistencies in the availability of data however, did not allow for 
statistical analyses. Despite this, a trend towards triglyceride elevations was evident from 
three months following transplantation, suggesting that this population show some 
characteristics of hypertriglyceridaemia. Other studies have confirmed that this lipid 
abnormality is evident following cardiac transplantation (Becker et al 1987; Keogh et al 
1988). However, in the present study, a high prevalence of hypertriglyceridaemia may 
not have been evident because of the small sample size, missing data and the selection of 
patients with normal liver and renal function. 
Although lipid elevations were determined to be significant at three months post-
transplant, it is important to recognise that in the present study, pre-transplant blood lipid 
levels were analysed at end-stage cardiac failure. Hence, blood lipids may have been 
artificially depressed by myocardial infarction, cardiac cachexia, elevated catecholamines 
and changes in gastrointestinal absorption, even in patients with known pre-transplant 
hyperlipidaemia and ischaemic heart disease (Ballantyne et al 1987). Pre-morbid lipid 
values would therefore provide a more valid comparison of pre versus post-transplant 
lipid elevations. Despite this, it is still notable that the mean three month post-operative 
cholesterol level of 6.1 ± 1.6 mmol/L is above the recommended range for total 
cholesterol, indicating that hypercholesterolaemia is an issue for the heart transplant 
population immediately post-transplant. 
Data on changes in lipoprotein cholesterol following cardiac transplantation were not 
available for analysis in this study. Other researchers have demonstrated that the 
lipoprotein profile of this population tends to be particulariy atherogenic. Stamler et al 
(1988) demonstrated that LDL cholesterol elevations were evident from two weeks 
following cardiac transplantation. The total cholesterol to HDL cholesterol ratio which 
correlates with cardiovascular risk was also found to increase throughout the first post-
transplant year. Other researchers have also reported transient increases in HDL 
cholesterol levels, however, these appear to stabilise within the first three months post-
transplant (Becker et al 1988; Ballantyne et al 1992). Although cholesterol sub-fractions 
were not reported in the present study, it is likely that the pattern of lipoprotein changes 
demonstrated by other researchers was similar for this population. 
The development of hyperlipidaemia in this population could be the result of a number of 
factors. Other researchers have shown that obesity is strongly associated with lipid 
elevations (Keogh et al 1988; Rudas et al 1990). Considering the high prevalence of 
overweight and obesity in this population, this is a potential contributing factor. The use 
of immunosuppressive medications may have played a role in this disorder, as all 
participants were receiving triple drug immunosuppression with cyclosporine, 
azathioprine and prednisone. Prednisone alone has been shown to elevate cholesterol and 
triglyceride levels by up to 10 and 20 per cent respectively (Bagdale et al 1970). The 
establishment of low maintenance doses of immunosuppressants may also explain the 
stabilisation of lipid values seen up to 12 months post-transplant. The administration of 
anti-hypertensive medications which in renal transplant patients has been associated with 
hyperlipidaemia (Vathsala et al 1989) was also frequent in this population. It is also 
possible that diet contributed to hyperlipidaemia, as the dietary intakes of fat and samrated 
fat were greater than desirable in a considerable proportion of patients. This is strongly 
associated with total cholesterol elevations (Kromhout et al 1989). In addition, physical 
activity, which has benefits for lipid profile including reductions in LDL cholesterol, was 
generally low for this population. 
Overall, the results of this study suggest that hyperlipidaemia is a cardiovascular risk 
factor which develops in a considerable proportion of transplant recipients following 
cardiac transplantation. It appears that this anomaly is particulariy a problem during the 
first three months post-transplant. Considering the predisposition to cardiovascular 
problems in this population and the negative implications of hyperlipidaemia for CAD 
development, close monitoring and tight control of blood lipid levels through 
pharmacological, dietary or lifestyle intervention may be beneficial to the cardiovascular 
health of this population. 
5.2 Body Weight 
Weight gain following cardiac transplantation has the potential to influence the 
establishment of other cardiovascular risk factors and possibly influence CAD 
development. The prevalence of overweight (BMI >25) in this population was 56 per 
cent at 12 months following transplantation. At the same time, one third of these patients 
were classified as obese (BMI >30). The findings of Grady and Herold (1988) suggest 
similar prevalence rates, with 51 per cent of transplant patients in their study population 
being overweight at six months following transplantation. This compares with more 
recent studies on post-transplant obesity by Lake et al (1993) who reported a 39 per cent 
prevalence of overweight at 12 months post-transplant, suggesting that weight gain 
appears to more widespread in the present study population. This variance may be due to 
an actual difference in weight gain in this study population or possibly be the result of 
difference in sample size or classifications of overweight and obesity. 
The temporal sequence of body weight changes in this study was an initial decrease in 
mean BMI from 24.7 pre-transplant to 23.9 (p<0.01) at one month post-transplant. This 
immediate post-transplant weight loss could be attributed to an acute post-surgical phase, 
infection or early rejection (Kumar and Coulston 1983). Alternatively, it is possible that 
significant decreases in mean weight did not actually occur, as pre-transplant weights 
were recorded at initial assessment for cardiac transplantation, often several months 
before transplant procedures. As a result, patients may have weighed less immediate pre-
transplant and at one month may have had similar body weights. Because cardiac 
transplantation is an emergency procedure and reliant on the availability of donor hearts, 
data on pre-transplant body weight at a comparable points in time for each recipient is not 
obtainable. 
Following immediate post-transplant weight loss, body weight increased progressively 
up to 12 months post-transplant with significant gains between each increment (p<0.01). 
The mean weight gain at 12 months from baseline was 7.8 kilograms in this study 
population. These findings are comparable to those reported by several other 
researchers. Grady and Herold (1988) demonstrated a mean weight gain of 7.4 
kilograms at six months post-transplant. Further changes in weight were not reported 
after this time. Hagan et al (1990) reported a slightly higher increase of 8.7 kilograms at 
one year in transplant patients maintained on corticosteroid therapy. In comparison, 
Keogh (1988) who undertook a previous study on the St. Vincent's Hospital transplant 
population reported a mean weight gain of 4 kilograms at 12 months after cardiac 
transplantation. The findings of a mean 12 month weight gain of 7.8 kilograms in the 
present study suggest that Keogh's recommendations for more stringent efforts at weight 
control have not been adequately implemented. In addition to this, patients self-
assessments of their own body weight suggests that weight not only returns to pre-
morbid levels, but in a large number of transplant recipients, actually exceeds pre-
transplant usual weight. As a result, the degree of weight gain in this group of patients 
may not only be unacceptable in terms of reference standards, but also exceed the patients 
own previously set-point for body weight. 
Although these findings suggest that body weight increases over time following cardiac 
transplantation, several factors which affect the accuracy of these results must be 
considered. Firstly, information regarding body weight was obtained from St. Vincent's 
Hospital medical records and not measured directly by the researcher. As a result, 
measurements were taken by a number of hospital staff and to differing degrees of 
precision (eg. 1.0 kg versus 0.25 kg). Also, height was obtained from pre-transplant 
records and although this was verbally confirmed with participants, it is not known if 
transplant patients were actually measured to obtain this data. In addition, the presence of 
oedema in this population, which occurs as a result of prednisone therapy may have 
potentially influenced any measures of body weight in this study. Finally, participants 
self-assessment of changes in body weight following transplantation may have been 
skewed by the fact that many were ill for a long period prior to the availability of a 
suitable donor heart. As a result, usual or healthy body weight may have been under-
estimated. 
Evidence suggests that the distribution of body fat is predictive of cardiovascular risk in 
the non-transplant population (Donahue et al 1987; Ducimetiere and Richard 1989; Hartz 
et al 1990). Although this has yet to be investigated in cardiac transplant recipients, it is 
likely that the presence of abdominal or android obesity has similar metabolic and 
cardiovascular complications for this population. Prior studies on the body composition 
of cardiac transplant patients have suggested that percentage body fat is increased and 
muscle mass is reduced (Ketayian et al 1992). However, the pattern of fat distribution in 
this population remains largely undescribed. One previous study undertaken with renal 
transplant recipients suggested that fat redistribution, as associated with 
immunosuppressive therapy in transplant patients was not evident (Horber et al 1986). 
In comparison to this, the findings of the present study which utilised the WHR and 
waist circumference suggested that an abdominal pattern of fat distribution was frequent 
in the post-transplant population. Eighty eight per cent of transplant recipients had WHR 
greater than recommended, whilst 33 per cent had a waist circumference in excess of 100 
centimetres. These indices suggest that abdominal obesity poses considerable 
cardiovascular risk to the transplant population. 
The limitations of the chosen methodology, however must be considered before making 
any conclusions regarding the body fat distribution of the transplant population. Other 
researchers have suggested that WHR may not be predictive of cardiovascular risk in 
individuals with a small hip circumference (Despres et al 1990). Measurements of the 
WHR also fail to distinguish visceral metabolically active fat from subcutaneous 
abdominal fat (Ross et al 1992). Whilst, in obese patients, difficulties in identifying 
measurements sites reduce the accuracy of the results. Further research into body fat 
distribution utilising other assessment techniques may provide more insight into the 
cardiovascular profile of this population. 
When compared to measures of overweight and obesity in the Australian population, the 
post-cardiac transplant population display a tendency towards higher mean body weights 
and waist circumferences. The mean BMI of men and women reported by the National 
Heart Foundation (1989) was 25.3 and 24.3 respectively. In comparison, the mean 12 
month post-transplant BMI in this population was high at 27.1. Additionally, the average 
waist circumference of 100.7 cm demonstrated in this study is considerably greater than 
the 89 cm for men and 76 cm for women reported by the National Heart Foundation. 
This evidence suggests that the transplant population may be at increased cardiovascular 
risk in regards to body weight than the general population. 
The cause of post-transplant weight gain in this population is most likely multi-factorial. 
Steroid administration however, appears to play a significant role. Other researchers 
have demonstrated that transplant recipients maintained on steroids, gain significantly 
more weight than those undertaking corticosteroid free maintenance therapy (Hagan et al 
1990). The mechanism for this effect has been laigely related to steroid induced appetite 
changes. In this study, 59 per cent of recipients reported that their present appetite (at 12 
to 24 months post-transplant) was excellent, while only 4 per cent suggested that appetite 
was poor. Poor appetite seemed to appear in patients who were ill at the time of the study 
or taking appetite altering medications. The majority of post-transplant recipients (81 per 
cent) also reported that their appetite had increased over the post-transplant period. As a 
result of altered appetite patients may exhibit energy intake in excess of physiological 
requirements, of which weight gain is the result. In addition to the adverse effects on 
appetite, steroids have also been shown to stimulate changes in body composition 
(Schneider et al 1977). Increased truncal or abdominal fat tends to be the result. Steroid 
administration in the present patients population may therefore also act to explain the high 
prevalence of abdominal obesity. 
A history of pre-transplant obesity has also been suggested to predict the development of 
overweight and obesity following cardiac transplantation ( Hagan et al 1990; Lake et al 
1993). The present study confirmed this. At 12 months post-transplant, nine of the 
participants in this study were obese (BMI >30). Retrospective analysis of weight 
records revealed that all of these patients were actually overweight (BMI >25) prior to 
transplantation. As a result, close monitoring of patients displaying a pre-transplant 
weight above desirable or with a history of overweight may assist in reducing the 
prevalence of this long-term complication of cardiac transplantation. 
Physical inactivity may also enhance weight gain in this population. Over a half of the 
transplant population were either exercising below the currently recommended 30 
minutes, three times per week or sedentary in their activity level. The combined effect of 
corticosteroids and physical inactivity, superimposed on a history of obesity may 
therefore contribute to the increased body weight seen in this group of patients following 
cardiac transplantation. 
The adverse implications of excessive weight gain in the transplant population are 
multiple. Overweight and obesity have been associated with elevations in total 
cholesterol, LDL cholesterol, triglycerides and reduced HDL cholesterol levels (Bonora et 
al 1991). Several studies have confirmed that weight gain is a key factor in lipid 
elevations in transplant recipients (Keogh et al 1988). The development of post-
transplant diabetes mellitus may also be related to some extent to weight changes (Hagan 
et al 1990), although has not been adequately investigated in this population, to date. 
Furthermore, inappropriate weight gain has been shown to exacerbate hypertension and 
adversely affect cardiac functioning, which in the long term may have deleterious effects 
on the integrity of the transplanted heart (Hagan et al 1990). 
Although weight gain is a concern for the cardiovascular health of the majority of 
transplant recipients, in a small number of patients weight gain in the post-transplant 
period may actually be beneficial. At one month post-transplant, five transplant recipients 
were below the healthy weight range as indicated by a BMI <20. Increases in weight, 
particularly fat free mass to achieve a weight appropriate to height, is therefore desirable 
for this sub-group of transplant recipients. 
The present study provides considerable evidence that body weight increases over time 
following cardiac transplantation. In general, this group of patients are inclined to be 
overweight with an android pattern of fat distribution, which indicates that they have a 
high risk profile for CAD development. Measures to alleviate this clinical problem would 
therefore be beneficial. It is possible that aggressive cardiac rehabilitation, pre-transplant 
weight reduction (in obese patients) and patient education may be a means of addressing 
the weight control issue. Whilst there is some evidence that behavioural techniques may 
achieve sustained weight reduction in this population (Robert et al 1990). Ultimately, the 
most appropriate intervention for attaining and maintaining a healthy body weight would 
be individualised, implemented early post-transplant and take into account the myriad of 
factors which impact upon the weight status of cardiac transplant recipients. 
5.3 Diabetes Mellitus 
Post-transplant diabetes mellitus is a significant long-term complication of cardiac 
transplantation. The prevalence of this disorder has been reported to vary from 8 to 14 
per cent depending on the definition used (Utresky et al 1987; Ladowski et al 1989). In 
the present study, a total of seven post-cardiac transplant patients displayed diabetes in 
the post-transplant period. Of these, two had diabetes prior to transplantation and the 
remaining five developed this complication in the post-transplant period. The resultant 
prevalence of post-transplant diabetes mellitus was therefore 19 per cent. Of these 
patients, two were maintained on insulin and the remaining five on oral hypoglycaemic 
agents. 
In the patient population studied for this research, blood glucose levels were not regularly 
available for analysis. Detection of diabetes mellitus in this population therefore tended to 
occur symptomatically, rather than early in the post-transplant period. It is plausible 
therefore, that a considerable proportion of these patients have undiagnosed diabetes 
mellitus. As a result, the actual prevalence rates for diabetes following cardiac 
transplantation would be much higher. The irregular blood glucose monitoring of these 
patients also failed to allow for any analysis of diabetic control or detection of the 
temporal sequence of diabetes development in this population. 
The underlying cause of diabetes mellitus in this population is likely to be the combined 
effect of immunosuppressive administration and post-transplant weight gain. Steroids 
are thought to induce diabetes via the effects on peripheral insuHn resistance and impaired 
glucose tolerance (Gardiner 1993). Cyclosporine on the other hand has been linked to 
similar metabolic changes, however this has yet to be demonstrated in this patient 
population. In this study, all transplant recipients were receiving both corticosteroids and 
cyclosporine. Weight gain, as common in this population, also corresponds to the 
development of insulin resistance and in the long term, decompensation of pancreatic 
function (Thomas 1994). As a result diabetes may have developed in a number of these 
patients as a result of inappropriate weight gain over the post-transplant period. 
In the present study, it was difficult to make any valid conclusions regarding post-
transplant diabetes mellitus, because of the limited amount of available data. Despite this, 
it is evident that the presence of diabetes mellitus in this population is likely to have 
negative implications for cardiovascular profile. As a result, early diagnosis, weight 
control and appropriate dietary intervention would be beneficia! to this patient population. 
5.4 Blood Pressure 
Hypertension is a significant complication of cardiac transplantation that has been 
reported to affect up to 90 per cent of all post-transplant recipients (Radovancevic et al 
1990; Renuld et al 1989). Although blood pressure elevations have not been 
unequivocally linked to post-transplant CAD, there is some evidence that this may be a 
contributing risk factor to the development of this disorder (Winters et al 1990; 
Radovancevic et al 1990). In this study, hypertension as defined by a diastolic blood 
pressure >95 mmHg or the administration of anti-hypertensive medications, was evident 
in 73 per cent of long-term transplant recipients. It is possible that the prevalence in this 
study was actually lower than that reported by other researchers because of the small 
sample size, the exclusion of patients with diagnosed renal impairment or the definition of 
hypertension used. 
Over time the development of hypertension tended to become more prevalent. 
Immediately post-transplant only 52 per cent of transplant recipients displayed this 
disorder. By six months post-transplant the prevalence of hypertension reached 67 per 
cent and by 12 months 73 per cent of this population were hypertensive. Although 
hypertension appears to be a frequent complication of transplantation, blood pressure was 
generally maintained within recommended limits in this group of patients. The mean 
diastolic blood pressure at 12 months post-transplant was 84 mmHg, whilst systolic 
blood pressure averaged at 134 mmHg. In the present study, none of the transplant 
recipients displayed persistent uncontrolled hypertension. It is likely that this is the result 
of close monitoring and pharmacological intervention in the post-transplant period. 
Although it is plausible that these results reflect the fact that blood pressure was measured 
only once at each point in time. Since the requirements for a diagnosis of hypertension 
require blood pressure elevations from consecutive readings, it is possible that blood 
pressure control or the prevalence of hypertension therefore, actually differed from these 
findings. However, in theory, if blood pressure is as well controlled as indicated by this 
study, complications for cardiac function and CAD development are likely to be 
minimised. 
In comparison to data from the Australian population, evidence from this study suggests 
that transplant recipients are considerable different from the general population in regards 
to the development of this disorder. Population studies, using the same blood pressure 
classifications as used in the present study, suggest that hypertension is present in 17 per 
cent of men and 13 per cent of women (National Heart Foundation 1989). The 73 per 
cent prevalence rate for hypertension in this study therefore indicates that other factors 
clearly play a role in this disorder. Despite this, the degree of blood pressure control was 
relatively similar to population levels. 
The underlying cause of hypertension in cardiac transplant patients has been most 
strongly related to cyclosporine administration (Myers et al 1984; Martin et al 1987). In 
this study, all patients were receiving immunosuppression with this medication over the 
post-transplant period, suggesting it as a probable underlying factor. However, the 
frequent development of blood pressure elevations in the pre-cyclosporine era of cardiac 
transplantation has suggested that other factors may contribute to this disorder (Ozdogan 
et al 1990). It is possible that blood pressure increased in response to post-transplant 
induced physiological changes (Shapiro et al 1990). This could not be examined in this 
study. Prednisone has also been implied as a causative factor. However in the present 
study, the prevalence of hypertension increased over time, whilst steroid administration 
was reduced. Hence this relationship is unlikely. Alternatively, weight gain which 
correspondingly increased over time with elevations in blood pressure may act to explain 
the prevalence of this disorder. This hypothesis is supported by evidence from non-
transplant populations which has strongly linked weight gain to elevations in blood 
pressure (Havlik et al 1983). 
Although blood pressure was on the whole, well controlled in this population, it could be 
hypothesised that a combination of weight reduction, sodium restriction and lifestyle 
modifications (eg. smoking cessation, physical activity) may alleviate the need for 
pharmacological treatment of this disorder. Although this has been demonstrated to be 
the case in the general population (Elmer et al 1991), few intervention studies including 
heart transplant recipients have been reported to date. However, until these studies 
provide more of an insight into possible treatment alternatives for this disorder, frequent 
monitoring and control of blood pressure, as is currently being implemented, should 
continue for these patients. Whilst non-pharmacological interventions should be 
encouraged as a complementary CAD preventative measure. 
5.5 Dietary Intake 
The goal of long-term nutritional therapy for the heart transplant recipient includes 
achieving reductions in total fat, saturated fat, cholesterol, alcohol and sodium, whilst 
increasing intakes of carbohydrate and dietary fibre (Frazier et al 1985). Although the 
efficacy of such a healthy heart diet in improving the cardiovascular profile of cardiac 
transplant recipients has not been widely reported, evidence from some researchers 
suggests that dietary modifications may positively influence blood lipids, blood pressure 
and body weight (Salen et al 1994; Singer et al 1994). In the present study, the intake of 
each of these dietary components was analysed for all participants using an extensive diet 
history. 
Fat intake is one dietary component which has implications for plasma lipids, lipoproteins 
and body weight. As a result, a high fat diet has been associated with an increased risk 
of cardiovascular diseases (Shrapnel et al 1992). In the present study, the fat intake of 
long-term cardiac transplant recipients contributed a mean 31.7 per cent of energy to the 
diet. This was significantly higher than the recommended <30 per cent of energy 
(p<0.05), however less than the average intake reported for the Australian population 
(Lester 1994). Thirty seven per cent of transplant recipients met the current 
recommendations for total fat intake and 26 per cent actually had a fat intake >35 per cent 
of energy. It is interesting to note however, that 51 per cent of transplant recipients 
indicated that they were following a diet which included reductions in total fat content. 
This suggests possible inaccuracies in dietary analysis or discrepancies between 
participants perceptions of what constitutes reductions in dietary fat and an actual low fat 
diet. Consequently, recommendations for reducing total fat intake and the means by 
which this can be achieved should be reinforced in the cardiac transplant population. 
The saturated fat intake of this population was also significantly higher than current 
recommendations (p<0.05). The mean intake of saturated fat 11.1 per cent of energy, 
whilst that which is recommended is less than 10 per cent of energy. Only one third of 
transplant recipients were currently consuming a saturated fat intake as desired. 
Reducing the saturated fat content of the diets of transplant recipients is therefore 
recommended. Salen et al (1994) provided evidence that such a dietary modification may 
be advantageous for the cardiovascular profile of this population, reducing both total 
cholesterol and LDL cholesterol levels. 
The cholesterol intake of this group of patients was also assessed in the present study. 
The mean cholesterol intake of 317 milligrams per day did not differ significantly from 
the maximum 300 milligrams per day as desired. Most participants in this study had low 
to moderate cholesterol intakes with only a small group of recipients greatiy exceeding 
recommendations. Overall, this suggests that transplant recipients generally adhere to 
low cholesterol dietary recommendations which may be beneficial to cardiovascular 
profile. 
Alcohol is considered to pose cardiovascular risk at high levels of consumption (Ahlawat 
and Siwach 1994). In this study, 37 per cent of cardiac transplant patients were non-
drinkers. The remaining 63 per cent reported low alcohol intake. Hence cardiovascular 
risk in terms of frequency and quantity of alcohol consumed was low for this population. 
In heart transplant recipients sodium restriction is recommended for blood pressure 
control and to eliminate the presence of oedema caused by steroid administration (Kumar 
and Coulston 1983). Previous studies on the cardiac transplant population have shown 
that blood pressure is sensitive to reduced sodium intake and that extremely low sodium 
diets can result in large decreases in systolic blood pressure (Singer et al 1994). 
Extrapolating these results, it is possible that a sodium intake at the recommended level of 
40 to 100 mmol per day can achieve modest blood pressure reductions. In this study, 
dietary analysis revealed that the mean sodium intake of this population was 121.9 mmol 
per day and that 71 per cent of transplant recipients had sodium intakes greater than 
recommended. It was also interesting to note that only a small proportion of transplant 
recipients actually reported the addition of salt to their diets, suggesting that sodium 
intake was obtained from other dietary sources. Hence, there is room for dietary 
intervention to reduce the sodium intake of this group of patients. 
An adjunct to the recommended low fat intakes for a healthy heart diet is an increase in 
carbohydrate and dietary fibre intake. The style of eating has been shown in general 
population studies to be beneficial for cardiovascular profile (Schaefer et al 1981; 
Anderson et al 1991). In the present study, carbohydrate intake as a percentage of energy 
was low at a mean 41.5 per cent. This was significantly less than the recommended 55 to 
60 per cent contribution to energy (p<0.01). Total daily fibre intake on the other hand 
was high and met the desired intake of 25 to 30 grams daily. This unusual dietary pattern 
is possibly the result of a high total energy intake, which may explain the high fibre yet 
low percentage energy contribution from carbohydrates. It could be assumed therefore, 
that a considerable proportion of transplant recipients were following dietary 
recommendations for increasing fibre intake. 
Overall, the results of this analysis suggest that the diets of a considerable proportion of 
transplant recipients exceed current recommendations for total fat, saturated fat and 
sodium. Dietary fibre intake tends to be high, whilst carbohydrate and alcohol intakes are 
on the whole, low. Before making any conclusions regarding the adherence with healthy 
heart recommendations in this population, however, the limitations of the chosen dietary 
assessment methodology must be considered. The diet history, like other techniques has 
several limitations in dietary assessment. Although it provides a good indication of usual 
intake it may neglect infrequently consumed food, inaccurately estimate or over-report 
intake (Thompson and Byers 1994). Thus any results must be interpreted with care. 
Although the underlying aetiology of post-transplant CAD is not necessarily diet related 
and the role of dietary intervention has yet to be proven in improving the cardiovascular 
profile of cardiac transplant recipients, promoting a diet which corresponds with a healthy 
heart pattern of eating is a safe means of promoting sound nutritional health whilst 
possibly achieving cardiovascular benefits. Although the diets of the heart transplant 
population more comparable with healthy heart guidelines than intakes reported in the 
general population, considering the predisposition to cardiovascular complications in 
transplant recipients, adherence with recommendations is vital. Thus cardiac transplant 
recipients who presently only receive immediate post-transplant dietary intervention may 
benefit from appropriate nutrition education and counselling extending beyond the initial 
post-transplant period. 
6. CONCLUSION 
The findings of this study suggest that the St. Vincent's Hospital heart transplant 
population have a high risk profile for the development of cardiovascular complications 
including post-transplant CAD. Although the development of these risk factors appears 
highly related to the metabolic consequences of immunosuppressive therapy and other 
factors unique to transplant recipients, there is some evidence that these risk factors are 
modifiable with appropriate preventative and treatment protocols. 
Hyperlipidaemia was a post-transplant cardiovascular risk factor which developed in this 
study population. At three months post-transplant, total blood cholesterol increased 
significantly from pre-transplant values and by 12 months post-transplant, 41 per cent of 
recipients were hyperlipidaemic. Although the prevalence and degree of this disorder 
was less than previously reported by other researchers, the combined effect of lipid 
elevations with immunological factors has the potential to influence CAD development. 
Overweight was possibly the most significant cardiovascular risk factor evident in the 
post-cardiac transplant population. Immediately following transplantation, body weight 
decreased in these patients. Ensuing this, weight increased progressively over time and 
significant gains were apparent at measurement interval. Measures of body fat 
distribution indicated a disposition towards abdominal obesity. Corresponding increases 
in appetite and low levels of physical activity were demonstrated in this population. 
Consequently, obesity may be significant not only in its independent effects on 
cardiovascular health but via its influence on the establishment of other risk factors 
including hypertension, diabetes mellitus and hyperlipidaemia. Thus it is possible that 
ameriolation of weight gain may be one of the most important CAD preventative 
measures. 
Diabetes mellitus was also evident in a small number of transplant recipients. The 
prevalence for this disorder being 19 per cent at 12 months post-transplant. However, it 
is possible that because of the presently inadequate blood glucose monitoring of these 
patients the prevalence of diabetes mellitus is much higher. It is likely that the combined 
effect of steroids and weight gain contributed to this disorder which has negative 
implications for cardiovascular profile. 
Hypertension was one of the most prevalent of all cardiovascular risk factors in this 
population affecting 73 per cent of transplant recipients. Analysis of blood pressure 
measurements however indicated that this disorder was well controlled in the transplant 
population. Hence the cardiovascular risk posed by this disorder is minimised. 
Comparison of the usual dietary intake of the cardiac transplant population with current 
healthy heart recommendations suggests that long-term adherence to dietary advice is 
sub-optimal in a considerable proportion of transplant recipients. Intakes of fat, saturated 
fat and sodium were generally greater than recommended, whilst carbohydrate intake was 
lower than desirable. Alcohol and cholesterol intakes on the other hand were within 
currently recommended levels. 
Overall, the evidence from this study suggests that the potential exists for improving the 
cardiovascular profile of long-term cardiac transplant recipients. With monitoring and 
appropriate intervention it is hypothesised that the development of CAD in this population 
could be delayed or even reduced. However, further studies incorporating larger samples 
of transplant recipients are required to substantiate this. 
7. RECOMMENDATIONS 
On the basis of the findings of this study it is recommended that: 
1. Blood lipid levels including both triglycerides and total cholesterol be regularly 
monitored in the post-transplant period. Transplant recipients who display undesirable 
lipid profiles which compromise cardiovascular health should be targeted for appropriate 
pharmacological, dietary or lifestyle intervention. Information regarding lipid 
subfractions, particularly LDL nad HDL cholesterol would also be beneficial in patient 
monitoring, however the cost effectiveness of such an approach needs to be considered. 
2. Weight gain in post-cardiac transplant patients be monitored at regular intervals and 
appropriate interventions implemented. A multi-disciplinary approach to the weight 
control issue should be encouraged. Medical and nursing staff who have regular contact 
with transplant recipients should identify inappropriate weight gain and target patients for 
intervention. Ideally, this would include referral to a clinical nutritionist and other allied 
health staff who are involved with lifestyle intervention (eg. physiotherapist, 
psychologist). The most appropriate intervention would consider all factors relevant to 
post-transplant weight gain (eg. appetite, quality of life, physical activity) and be 
individualised to meet the patients requirements. Group education may also be effective 
as the group dynamics for this small population of patients is likely to be positive. 
3. Waist-to-hip ratio be routinely measured as an assessment of cardiovascular risk. This 
would be particularly important in this population who are susceptible to increased central 
or android adiposity as a consequence of steroid administration. In such routine 
measurements, standard sites and acceptable cut-off ratios should be pre-determined. 
4. Blood glucose levels be monitored at regular intervals following cardiac 
transplantation. This would allow for early identification of diabetes mellitus and suitable 
medical and nutritional intervention. In turn, this may act to delay the progression of 
complications (including CAD) through the establishment of good blood glucose control. 
5. Blood pressure continue to be monitored to the present level and interventions to 
control hypertension implemented m the early post-transplant period. 
6. Transplant recipients receive long term dietary follow-up from a clinical nutritionist. 
Healthy heart dietary guidelines should be reinforced with the aim of achieving acceptable 
lipid, weight and blood pressure profiles. The most effective intervention should 
incorporate practical aspects of improving dietary intake and focus on what foods are 
appropriate for consumption rather that those which are not. 
7. Exercise be encouraged in this population both for cardiovascular benefits and weight 
control. This should include the currently recommended minimum of 30 minutes at least 
three times per week. 
8. LIMITATIONS 
The present study was limited by: 
1. Small sample size 
Due to time and resource constraints, only 27 cardiac transplant recipients could be 
included in the present study. Had a larger sample size been included, the significance 
these findings may have been stronger. 
2. Missing Data 
As information was obtained from pre-existing medical records, data collection was 
limited by information not recorded in medical records. This was particularly the case 
with blood lipid analysis. 
3. Dietary intake methodology 
The diet history method used to collect dietary intake data in this study is subject to 
inaccuracies, related to the large subjective component of this method, the reliance on 
participant memory and the degree of estimation involved with this technique. As a 
result, this dietary information gathered in this study may have been subject to over or 
underestimation. 
4. Accuracy of retrospective data 
Body weight was measured by a variety of different hospital staff and to differing 
degrees of precision. As a result, measurements of weight in the present study are 
subject to potential inaccuracies. 
For a diagnosis of hypertension, blood pressure elevations are required over three 
consecutive readings. However, because blood pressure was retrospectively analysed 
from medical records only one reading for each time period was available in this study. 
Hence, the actual blood pressure of participants may have differed from recorded 
readings. 
5. Failure to examine all cardiovascular risk factors 
Other cardiovascular risk factors (eg. smoking) were not examined in the present study. 
Hence the existence of multiple risk factors could not be adequately determined in this 
study. 
9. AREAS FOR FURTHER INVESTIGATION: 
Since heart transplantation is a relatively new procedure and the long-term complications 
are only just being recognised, there are at present many areas for investigation which 
have yet to be fully examined in the literature. These include: 
1. The effectiveness of dietary intervention in preventing cardiovascular 
complications such as CAD. (eg. the effectiveness of a low fat diet in reducing 
hyperlipidaemia, reducing sodium intake to control blood pressure etc.) A number of 
studies have included diet as a component of the overall investigation however, to date, 
large controlled studies in this area are absent. Such a study would provide evidence as 
to whether more stringent healthy heart recommendations need to be developed for the 
cardiac transplant population. 
2. The most effective means of achieving sustained weight control in this 
population. Excessive weight gain has multiple implications for the long term health of 
transplant recipients. To date, there is little information regarding the most effective way 
to alleviate this clinical problem. 
3. The relationship between cardiovascular risk factors and the 
development of CAD. Although this has been previously reported in the literature, 
conclusions regarding the role of the different risk factors in the establishment of CAD 
remains controversial. Further research is needed to elucidate contributing factors. 
4. The prevalence of diabetes mellitus in this population, risk factors for 
the development of this disorder and blood glucose control. To date in the 
literature, little has been reported on post-transplant diabetes mellitus. This could not be 
thoroughly examined in this study, due to infrequent monitoring of blood glucose levels. 
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11.1 Project Approval Information 
11.2 Letter to Cardiac Transplant Patients 
9th August 1995 
Dear 
I am writing to ask you to take part in a study to help prevent long term health problems 
in heart transplant patients. It is being conducted by Clinical Nutritionists at St. 
Vincent's Hospital, in conjunction with a student from the University of Wollongong. 
As a heart transplant recipient, the information that you provide could help us to 
understand more about the incidence of heart disease and risk factors such as high 
blood cholesterol, overweight and diabetes in heart transplant patients. 
In turn, it may help to improve the nutrition services provided to heart transplant 
patients such as yourself. 
To gather this information, we are contacting a group of people who have received 
heart transplants at St. Vincent's Hospital, Sydney. You are one of those people and 
we would great;ly appreciate your help with this study which involves: 
• Measuring your weight and height 
• Measuring your waist and hips with a tape measure 
• You telling us about your usual diet and appetite 
• Obtaining information form St. Vincent's Hospital medical records about your 
cholesterol levels, triglyceride levels, body weight and blood sugar levels 
• Obtaining information regarding your age, medications and diagnosis from St. 
Vincent's Hospital medical records 
For us to collect this information, we will contact you to arrange an appointment here at 
St. Vincent's Hospital or an alternative venue if more convenient. The appointment 
will be for approximately one hour between August and October 1995. 
If you agree to participate, your identity will not be revealed and all information will be 
treated with the strictest confidence. If you decide not to take part or withdraw from the 
study, this will in no way affect the services provided to you by St. Vincent's Hospital. 
In the strong hope that you will participate, I will be contacting you by telephone with 
the next few weeks. 
In the mean time, if you have any questions or queries, feel free to contact Melinda 
Morrison or Clare Rawcliffe at St. Vincent's Hospital on (02) 361 2552. 
Thank you, in anticipation of your help. 
Yours Sincerely 
Melinda Morrison 
Student 
Department of Public Health and Nutrition 
University of Wollongong 
Clare Rawcliffe 
Clinical Nutritionist 
St. Vincent's Hospital 
11.3 Standard Consent Form 
CONSENT FORM 
ST. VINCENT'S HOSPITAL / UNIVERSITY OF WOLLONGONG 
FORM FOR RESEARCH STUDIES 
Project Title: 
The cardiovascular profile and dietary intake of post-cardiac transplant patients 
Investigators: 
Di Cheah 
BSc (Nutiition/Biology), MDAA, SRD (UK) 
Deputy In Charge, Nutrition Services 
St. Vincent's Hospital 
Melinda Monison 
BSc (Nutrition) 
Student (Master of Science (Nutrition & Dietetics)) 
University of Wollongong 
Clare Rawcliffe 
Dip. Home Science, MDAA 
Clinical Nutritionist, Cai'diopulmonai y Transplant Unit 
St. Vincent's Hospital 
Boris Gazibaiich 
BSc, Grad. Dip Diet MCom 
Lecturer and Academic Supervisor 
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1. You are invited to participate in the experiment described below which is 
being conducted as a pai t of the Master of Science in Nutrition and Dietetics 
degree at the University of Wollongong . 
2. Background to experiment 
Heait disease is the most frequently observed long term complication of heart 
tiansplantation. Risk factors for heart disease include obesity (particularly 
abdominal), high blood pressure, high cholesterol and triglyceride levels and a 
diet high in fat, salt and low in dietary fibre. 
The aim of this study is to find out more about the occurrence of these risk 
factors for heait disease in heait transplant recipients from St. Vincent's 
Hospital, Sydney. 
Forty heait transplant recipients from St. Vincent's Hospital have been 
selected to paiticipate in this study. These participants must be over the age 
of eighteen, have received a heart transplant within the past twelve to twenty-
four months and have no other medical conditions (eg. cancer, kidney disease, 
liver disease or pancreatic disease). 
It is hoped that this study will assist the Department of Nutrition Services in 
identifying aieas which require further dietary intervention. 
3. Description of Experiment - methods and demands 
The study involves : 
• Obtaining information from hospital medical records including: cholesterol 
levels, triglyceride levels, body weight, initial diagnosis, sex, age and current 
medications 
• An interview to obtain inforaiation regarding your usual dietary intake 
• Measuring body weight and height 
• Taking waist and hip measurements using a tape measure 
It is expected that the study will take approximately one hour. 
All of the information obtained in this study will be recorded in writing and 
stored at St. Vincent's Hospital. Only the researchers will have access to this 
information and it will not be used for reasons other than those intended in 
the reseai'ch. The data will be analysed and may be published in a medical or 
nutrition journal. Paiticipants identities will not be revealed in any published 
results. 
4. I acknowledge that I have read the above statement which explains 
the nature and object and the possible risks of the investigation, and the 
statement has been explained to me to my satisfaction. Before signing this 
document I have been given the opportunity to ask questions relating to any 
possible physical and mental harm I might suffer as a result of my 
participation and I have received satisfactory answers. I have also been 
informed that I may not receive any benefits from participating in this study. 
5. My decision whether or not to paiticipate will not prejudice my future 
relations with St. Vincent's Hospital and the University of 
Wollongong. If I decide to paiticipate, I am free to withdraw my consent and 
to discontinue paiticipation at any time without prejudice. 
6. I agree that reseaich data gathered from the results of the study may 
be published provided my name is not used. 
DATE Signature of Patient or Authorised 
Representative 
7. I have fully explained to the patient the nature 
and purpose of the program and the procedures to be employed as 
described above and such risks as ai'e involved in their performance. 
DATE Signature of Responsible 
Investigator 
8. The foregoing is an accurate summary of the explanation which was made to 
the patient/volunteer, and the undersigned witnessed the 
signatures. 
DATE Signature of Auditor-Witness 
NB. If you have enquires regaining the conduct of the research, please contact The 
Secretary of the University of Wollongong Human Research Ethics Committee on 
(042) 213079 
11.4 Data Collection Sheets 
DATA COLLECTION SHEET 
Participant Identification No.: 
Date: 
Sex: 
DOB: 
Date Transplant: 
Initial Diagnosis: 
Medications: 
• HT • CHOL • DM 
Biochemistry: 
Month T.Cho BSL's TG's B.P. |Wt. 1 BMI 
0 
1 
3 
6 
12 1 
18 1 1 
24 1 1 
Anthropometry 
Weight (kg): Height (cm): BMI: 
Waist (cm): #1: #2: 
Hips (cm): #1: #2: 
WHR: 
FOOD FREQUENCY CHECKLIST 
How many times each day / week would you eat the following foods: 
/ Food Daily Weekly Type 
Bread 
Breakfast Cereal 
Pasta / Noodles 
Rice 
Fruit 
Green Vege 
Orange Vege 
White Vege 
Milk 
Cheese 
Yoghurt 
Cream / Sour Cream 
Eggs 
Red Meat 
Chicken 
Fish 
Processed Meats 
Cakes 
Biscuits 
Chocolates 
Confectionary 
Nuts 
Crisps / Snack Foods 
Ice Cream 
Soft Drinks 
Cordials 
Alcohol 
Mayonnaise / sauces 
/ gravies 
Salt 
Pepper 
Food Preparation Data 
What kind of butter / margarine do you use?. 
What kind of oil do you fry in? 
What cuts of meat do you most commonly 
use? 
Do you eat the fat on meat? 
How do you prepare your meat / fish / 
chicken? 
How do you prepare your vegetables? 
What kinds of ready made / processed foods do you 
eat? 
Do you eat out or have take away's? How 
often? 
Have you seen a dietitian before? 
Are you presently following any kind of special diet? If 
yes, what kind? 
How would you describe your appetite at present? 
POOR GOOD EXCELLENT 
Have you noticed any changes in your appetite since 
your transplant? 
INCREASED DECREASED NO CHANGE 
Have you noticed any changes in your weight since your 
transplant? 
INCREASED DECREASED NO CHANGE 
Do you participate in any regular exercise? If yes, what 
and how often? 
11.5 National Heart Foundation Standards 
for Alcohol Risk 
Risk Levels 
Category Description Males Females 
A Non-drinkers 
B Average intake less 3 drinks None Low 
C Average intake of 4 drinks or 
9-12 drinks in any day 
Low Intermediate 
D Average intake of 5-8 drinks or 
occasional excess 
Intermediate High 
E Average intake of 9-12 drinks 
or frequent or great occasional 
excess intake 
High Very High 
F Average daily intake over 12 
drinks 
Very High Very High 
Amount: No. of drinks 
Frequency of Drinking 1-2 3-4 5-8 9-12 13-20 >20 
Less than once week B B B C D E 
1 or 2 days B B B C D E 
3 or 4 days B B C D E F 
5 or 6 days B C D E F F 
Every day B C D E F F 
11.6 Raw Data 
MONTH 
Pt. Pre-op 1 3 6 12 18 24 
1 3.4 7.9 5.4 5.6 
2 5 7.3 6 
3 6.8 5.1 4.7 4.8 
4 4.8 5.54 
5 3.9 5.5 6.5 5.3 6 
6 5.6 4.9 5.6 5.5 5.3 
7 4 4.7 4.7 3.5 4.7 
8 4.6 5.9 6 6.3 6.8 
9 5.2 8.9 7.7 6.2 5.9 
10 7.5 5.9 5.8 6.6 5.8 
11 4.8 6 6.1 6 6.2 
12 3.4 5.2 5 
13 3.8 5.3 4.4 4.3 
14 2.9 5.8 5.2 5.4 
15 2.3 3.2 4.2 4 3.9 
16 5.9 7.5 7.4 6.7 6.9 5.9 
17 5.1 6 6.7 5.5 5.6 
18 6.3 5.7 6.2 5.3 4.4 
19 3.5 5.6 7.2 6.5 6.9 
20 3.7 7.2 6.1 4.7 4.7 
21 4.8 4.4 3.9 4.5 4.3 4.9 
22 5.6 6 10.6 7.8 6.6 5.8 
23 3.4 5.4 5.8 5.5 5.7 
24 
25 6.4 11.8 8.1 5.7 
26 3.1 5.2 
27 2 5.3 6.3 4.8 
1. Cholesterol Levels 
MONTH 
Pt. Pre-op 1 3 6 12 18 24 
1 0.7 
2 3 2.88 2.2 
3 3.8 2.8 2.5 2.3 
4 1.3 0.97 
5 0.7 1.1 0.89 0.9 0.9 
6 1.4 
7 1 1.3 1.16 1.41 1.46 
8 1.4 1.7 1.2 1.9 1.9 
9 2.5 3.9 3.4 2.73 
10 3.5 
11 1.7 2.8 4.1 2 2.7 
12 1 1 1 
13 1.1 
14 1.2 1.5 1 1.8 
15 
16 2.08 2.26 2.5 2.6 1.7 
17 0.7 
18 1.5 
19 1.3 1.1 1.6 1.5 
20 1.5 
21 2.9 1.6 1.4 1.7 2.2 
22 3 
23 0.9 1.02 1.1 1.2 1.5 
24 
25 1.2 1.1 
26 1.2 1.7 
27 
2. Triglyceride Levels 
MONTHS 
Pt. Pre-op 1 3 6 12 18 24 
1 20 20 21 23 23 
2 29 27 28 32 35 
3 25 22 24 25 27 29 
4 25 25 27 27 27 
5 19 20 21 22 23 24 
6 24 22 22 23 22 
7 21 21 21 22 21 22 23 
8 27 24 29 30 31 33 
9 26 25 28 29 30 33 
10 25 24 23 23 23 
11 21 20 21 23 24 25 
12 20 20 21 22 22 
13 21 19 19 22 20 
14 26 24 27 29 31 
15 25 25 26 26 25 
16 28 29 30 30 34 33 
17 28 27 26 27 28 
18 26 25 26 27 27 
19 22 20 20 24 25 25 24 
20 22 23 23 23 24 
21 26 24 25 28 32 33 33 
22 29 28 29 28 27 
23 25 25 28 29 31 36 
24 27 25 27 27 28 
25 28 29 30 31 33 33 
26 32 34 33 34 37 43 
27 22 20 22 23 23 23 
3. Body Mass Index 
NUTRIENT 
Energy Total Fat Saturated Fat Mono Fat Poly Fat Protein Carbohydrate Fibre Sodium Cholesterol 
Kilojoules Grams Grams Grams Grams Grams Grams Grams mmol Milligrams 
Pt . 
1 8706.3 83.7 24.9 37,4 10.5 133.6 199.1 31.7 1185 388.2 
2 9636.3 68.9 28.2 24.6 8.8 126.2 297 iin 150,6 359 
3 7940.5 67.5 27.3 22.8 11.7 99 227.8 26.5 85,5 239 
4 7801 54.4 23.7 18.7 lA 107.9 239.4 29.4 188,2 223.4 
5 11344.6 100.1 25.5 36.3 30.2 151.1 211A 32.4 113.1 321.4 
6 14260 146.1 52.9 61.3 17.9 219.7 330 30.9 132.8 605.4 
7 13968 116.8 43.5 44.7 13.8 130.7 409.2 38 158 297 
8 6724 50.9 13.1 21 10.6 101.5 127.4 28.8 70 249.2 
9 7947.1 63 16.7 31.1 15.2 112.6 208.8 33.-7 \sin 166.6 
10 10526 80.2 30.9 27.7 14.7 125.8 273.4 21.3 111 358 
11 7742 62.9 20.1 22 14.7 98.1 219.8 21.9 140.5 256 
12 6892 44.4 18.3 16.1 4.8 95 213.1 21.5 95.1 198.4 
13 12149.9 128.1 64.2 44.8 18.9 144 291.5 29.8 132.8 436.9 
14 13273 118 29.9 56.2 18.7 154.9 287.3 56.1 142.2 346.5 
15 14471.2 149.7 52.8 53.8 31.9 118.3 406.6 29.1 214.9 280 
16 8152 71.4 30 27.4 6.8 133.7 151.3 21.1 61.8 284.4 
17 10806 107.5 40.4 43.6 13.7 134.7 210.2 24.3 84 296.5 
18 11247 69 22.8 21.5 11.2 144.6 373.3 63.8 117 207 
19 15673 172.8 60.1 76.7 17.1 278.8 259.9 31 72.6 879 
20 10640 99.3 31.9 34.2 26.1 131.8 228.6 19.7 140.7 493.6 
21 7538 63.4 20.9 27.6 8.1 72.9 185.3 30.8 83.2 134.7 
22 10780 89.5 33.1 32.2 16.5 126 319.5 33.2 122 316 
23 9280 77.2 23.6 35 12.3 111 220.3 20.8 112 192.4 
24 12685.5 117.5 58.6 39.5 9 134.5 347.7 32.3 11L9 249.9 
25 7930.8 60.6 15.4 23.1 17.1 78.2 258.8 35.7 71.1 122.8 
26 13229.7 128.7 50.7 48 30 117 297.1 220.1 113 316 
27 10763.5 74.9 21.6 22.2 23 165.2 299.1 54.5 134.2 326.7 
4. Nutrient Intakes 
MALE 
Pt Mean Waist Mean Hip WHR 
1 110 107 1.03 
2 84.5 88 0.96 
3 117 119 0.98 
4 93 97 0.95 
5 124.5 108 1.15 
6 94 95 0.989 
7 86 90 0.95 
8 84 91 0.92 
9 113 103 1.09 
10 93.5 97 0.96 
11 110 108 1.02 
12 85 89.5 0.94 
13 119 113 1.03 
14 114 104 1.09 
15 85 89 0.96 
16 89 93 0.96 
17 91.5 89 1.02 
18 97.5 93 1.05 
19 91 87 1.04 
20 126.5 119 1.06 
21 94 94 1 
22 132.5 120 1.1 
23 91.5 90 1.02 
FEMALE 
24 128 143.5 0.89 
25 87 116 0.75 
26 89 116 0.77 
27 89 111 0.8 
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